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Summary	
Statins,	 hydroxyl-methyl-glutaryl-coenzyme	 A	 (HMG-CoA)	 reductase	 inhibitors,	are	 cholesterol-lowering	 drugs	 that	 are	 majorly	 used	 to	 treat	hypercholesterolaemia	 and	 dyslipidaemia	 implicated	 in	 the	 pathogenesis	 of	coronary	 heart	 disease	 and	 atherosclerosis	 [1].	 They	 are	 generally	 considered	safe	 drugs,	 but	 there	 are	 a	 number	 of	 reports	 of	 skeletal	 muscle	 damage	associated	 with	 their	 use	 [2].	 The	 myotoxicity	 ranges	 from	 a	 mild	 clinical	syndrome	consisting	of	benign	myalgia	to	rare	but	life-threating	rhabdomyolysis	[3].	 These	 side-effects	 can	 impact	 on	 quality	 of	 life	 and	 compliance,	 and	 in	extreme	cases	lead	to	death	[4].		Because	millions	of	people	in	the	world	are	currently	taking	statins	every	day,	it	is	an	urgent	task	to	uncover	the	mechanism	by	which	statins	lead	to	side	effects	[5].	This	thesis	includes	two	published	papers	and	one	still	in	preparation.		Our	 first	 paper	 presents	 a	 comparison	 between	 three	 different	 statins	 on	 the	market:	 simvastatin,	 atorvastatin	 and	 rosuvastatin.	 Since	 there	 are	 differences	among	 statins	 in	 terms	 of	 their	 efficacy	 and	 toxicity,	 we	 aimed	 to	 analyze	 the	different	 molecular	 mechanisms	 that	 may	 contribute	 to	 the	 diverse	 grade	 of	toxicity	between	simvastatin,	atorvastatin	and	rosuvastatin.		Simvastatin	 and	 atorvastatin	 appear	 to	 have	 a	 higher	 than	 average	 risk	 of	myotoxicity	 contributing	 to	 the	 highest	 number	 of	 cases	 of	 rhabdomyolysis	among	statins	[6]	[7].	On	the	contrary	rosuvastatin,	the	most	hydrophilic	statin,	appears	to	have	a	reduced	myotoxicity	[8]	[7].		C2C12	myotubes	were	exposed	to	10	µM	or	50	µM	simvastatin,	rosuvastatin	or	atorvastatin	 for	 24	 hours.	 We	 demonstrated	 that	 myotubes	 were	 more	susceptible	 to	 simvastatin	 and	 atorvastatin	 than	 to	 rosuvastatin	 treatment.	Therefore,	 difference	 between	 rosuvastatin	 and	 atorvastatin	 or	 simvastatin	could	point	to	possible	mechanisms	of	toxicity.		The	 cytotoxicity	 of	 simvastatin	 and	 atorvastatin	was	 associated	with	 a	 drastic	and	dose-dependent	impairment	of	AKT	signaling	cascade	that	led	to	inhibition	
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of	 the	protein	 synthesis,	 increase	of	 the	protein	degradation	 and	promotion	of	apoptosis.	 Conversely,	 rosuvastatin	 blocked	 AKT	 signaling	 only	 at	 high	concentration	and	 to	 a	 lesser	 extent	 compared	with	 the	other	 two	 statins.	The	reduced	effect	on	cytotoxicity	and	AKT	signaling	 inhibition	 in	C2C12	myotubes	treated	with	 rosuvastatin	was	accompanied	with	normal	protein	 synthesis	and	absence	 of	 protein	 degradation	 and	 apoptosis.	 These	 results	 provide	 evidence	that	 an	 impairment	 of	 AKT	 signaling	 pathways	might	 be	 a	 causative	 factor	 in	statin-induced	myotoxicity.		Our	 second	 paper	 expands	 on	 these	 previous	 results	 by	 showing	 that	 the	myotoxicity,	and	with	 it,	 the	 impairment	of	AKT	signaling,	can	be	prevented	by	the	addition	of	IGF-1.		IGF-1	 is	well	 known	 for	 exerting	 an	 anabolic	 effect	 on	 skeletal	muscle	 [9]	 	 by	activating	 IGF-1/AKT	 pathway	 [10].	 Therefore	 we	 investigated	 whether	 IGF-1	could	antagonize	the	myotoxicity	induced	by	statins.	Myotubes	 were	 exposed	 to	 10	 µM	 simvastatin	 and/or	 20	 ng/ml	 IGF-1	 for	 18	hours.	 Simvastatin-induced	myotoxicity	 was	 completely	 antagonized	 by	 IGF-1.	Moreover,	 the	protective	effect	of	 IGF-1	was	mediated	by	the	activation	of	 IGF-1/AKT	pathway	that	led	to	a	suppression	of	atrophic	markers	and	apoptosis,	and	simultaneously	 triggered	 pro-synthetic	 pathways.	 These	 studies	 provide	 new	insight	into	the	prevention	of	statin	toxicity	and	may	herald	new	discoveries	for	the	treatment	of	statin-induced	myalgia.			The	 final	paper	 takes	 the	work	of	 the	previous	 two	papers	and	places	 it	 into	a	novel	 system:	 the	 cardiac	muscle.	 Statins	 are	 primarily	 prescribed	 to	 cure	 and	prevent	 cardiovascular	 disease.	 Thus,	 cardiac	 side-effects	 may	 be	 masked	 by	falsely	attributing	them	to	the	underlying	disease.		In	 this	 paper,	we	 investigated	 on	 the	 effect	 of	 simvastatin	 in	 cardiomyocyte	 in	
vitro	and	 in	vivo.	We	treated	H9c2	rat	cardiomyocytes	with	10	µM	and	100	µM	simvastatin	 for	 24	 hours.	 H9c2	 cells	 showed	 a	 reduction	 in	 the	mitochondrial	membrane	 potential	 and	 energetic	 impairment	 linked	 to	 mitochondrial	dysfunction.	Consequently,	 the	cellular	ATP	 level	was	decreased.	This	decrease	led	 to	 the	 activation	 of	 AMPK,	 nuclear	 translocation	 of	 FoxO3,	 upregulation	 of	atrogin-1	 and	 initiation	 of	 apoptosis.	 We	 confirmed	 these	 results	 in	 vivo.	 We	demonstrated	 that	 the	 treatment	of	mice	with	simvastatin	5	mg/kg/day	 for	21	
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days	impaired	the	activity	of	several	enzyme	complexes	of	the	electron	transport	chain	 in	 cardiomyocytes	 and	 increased	 mRNA	 expression	 of	 atrogin-1	 and	markers	 of	 apoptosis.	 This	 is	 the	 first	 study	 that	 shows	 energetic	 impairment	linked	 to	 atrophy	 and	 apoptosis	 induced	 by	 statins	 in	 the	 heart,	 and	warrants	further	investigation	to	assess	statin	safety	in	susceptible	patients.	
	 		
	 4	
	 		
	 5	
Introduction	
1	Statins	
The	3-hydroxy-3-methylglutaryl	coenzyme	A	(HMG-CoA)	reductase	inhibitors,	or	statins,	are	a	class	of	drugs	used	to	reduce	blood	cholesterol	 level.	They	inhibit	the	 synthesis	 of	 cholesterol	 binding	 to	 the	 enzyme	 HMG-CoA	 reductase	 at	nanomolar	 concentrations	 and	 leading	 to	 competitive	 displacement	 of	 the	natural	 substrate,	 HMG-CoA,	 which	 binds	 only	 at	 micromolar	 concentrations	(Fig.	1).			
	
Fig.	 1.	 Mechanism	 for	 statin	 inhibition	 of	 HMG-CoA	 reductase.	 Statins	competitively	 inhibit	HMG-CoA	 reductase	 leading	 to	 competitive	 displacement	of	the	natural	substrate,	HMG-CoA		HMG-CoA	reductase	 is	 the	 first	 and	 the	 rate-limiting	enzyme	of	 the	 cholesterol	biosynthesis.	 It	 catalyzes	 the	 conversion	 of	 HMG-CoA	 to	 mevalonic	 acid	 [11]	[12](Fig.	2).	
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Fig.	 2.	 Schematic	 representation	 of	 cholesterol	 biosynthetic	 pathway.	Cholesterol	is	a	27	carbons	compound	synthesized	from	acetyl-CoA	which	is	the	precursor	to	all	sterol	molecules.	First,	Acetyl-CoA	is	converted	to	3-hydroxy-3	methylglutaryl-CoA	 (HMG-CoA)	 by	 HMG-CoA	 synthase.	 Then,	 HMG-CoA	 is	converted	 to	 mevalonate	 by	 HMG-CoA	 reductase,	 the	 rate-limiting	 enzyme	 of	cholesterol	biosynthesis.	Through	a	series	of	other	intermediates,	mevalonate	is	converted	 to	 cholesterol.	 Cholesterol	 is	 either	 synthesized	 de	 novo	 in	hepatocytes	 or	 absorbed	 from	 the	 diet.	 Inhibition	 of	 HMG-CoA	 reductase	 by	statins	 curtails	 not	 only	 hepatic	 cholesterol	 but	 also	 all	 isoprenoid	intermediates.	 Insufficient	 levels	 of	 isoprenoid	 species	 (i.e.	 geranyl	pyrophosphate	 and	 farnesyl	 pyrophosphate)	 cause	 numerous	 cellular	disfunctions,	 including	 altered	 cell	 signaling	 by	 inhibition	 of	 prenylation,	 a	crucial	 post-translational	 modification	 for	 many	 proteins,	 loss	 of	 membrane	integrity	due	to	deficient	cholesterol	synthesis,	etc.			In	addition,	the	decreased	cholesterol	production	in	the	liver	is	accompanied	by	an	 increased	synthesis	of	hepatic	LDL	receptors,	which	promotes	the	clearance	of	 low-density	 lipoprotein	(LDL)	and	very	 low	density	 lipoprotein	(VLDL)	 from	the	bloodstream	[13]	(Fig.	3).	While	all	statins	share	the	pharmacophore	(a	dihydroxyheptanoic	acid	segment	unit	and	a	ring	system	with	different	substituents)	responsible	for	the	binding	to	HMG-CoA	reductase,	 important	differences	exist	 among	statins	 that	distinguish	their	synthesis,	lipophilicity,	pharmacokinetic	properties,	drug-food	interactions	and,	LDL-lowering	potency	[14].		
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Fig.	 3.	 Cholesterol-lowering	 action	 of	 statins.	 Statins	 inhibit	 HMG-CoA	reductase	 leading	to	a	 final	decrease	in	the	 intracellular	content	of	cholesterol.	To	 compensate	 this	 diminution,	 cells	 respond	 increasing	 the	 number	 of	 LDL	receptors	on	the	cell	membrane,	Consequently,	the	LDL	is	taken	up	more	rapidly	and	its	level	in	the	plasma	falls.			Statins	are	commonly	classified	into	two	types:	type	1,	natural	or	fungal-derived	statins,	and	type	2,	synthetic	statins.	The	 functional	difference	between	natural	and	synthetic	statins	relies	on	their	ability	to	 interact	and	inhibit	 the	HMG-CoA	reductase	 and,	 on	 their	 lipophilicity	 [15].	 Type	 1	 statins	 (i.e.	 lovastatin,	pravastatin	and,	simvastatin)	(Fig.	3)	exhibit	binding	via	a	decalin-ring	structure	that	resemble	the	first	statin	ever	discovered,	mevastatin	[16].	Differences	 in	 statin	 structure	 and	 binding	 characteristics	 may	 partially	contribute	 to	 differences	 in	 the	 inhibition	 of	 HMG-CoA	 reductase	 efficacy	 and	other	 pharmacologic	 properties.	 For	 example,	 rosuvastatin	 is	 one	 of	 the	 most	potent	 statin,	 it	 is	 relatively	 hydrophilic,	 it	 has	 a	 greater	 number	 of	 bonding	interactions	with	the	catalytic	site	of	HMG-CoA	reductase	compared	with	most	of	the	other	statins	and,	it	is	the	most	well	tolerated	statin	in	the	market	[14].	Type	2	 statins	 (i.e.	 fluvastatin,	 cerivastatin,	 atorvastatin,	 and	 rosuvastatin)	 (Fig.	 5)	exhibit	additional	binding	via	their	fluorophenyl	group	[17].		 	
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Fig.	 4.	Type	1	 statins.	Lovastatin,	pravastatin	and	simvastatin	exhibit	binding	via	a	decalin	ring	structure.	 		
	
Fig.	 5.	 Type	2	 statins.	Fluvastatin,	cerivastatin,	atorvastatin	and,	rosuvastatin	have	larger	groups	linked	to	the	HMG-like	moiety	than	the	type	1	statins.	One	of	the	main	differences	between	the	type	1	and	type	2	statins	is	the	replacement	of	the	butyryl	group	of	type	1	statins	by	the	fluorophenyl	group	of	type	2	statins.		
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1.1	Why	study	statins?	Statins	 are	 widely	 used	 to	 prevent	 cardiovascular	 disease	 (CVD)	 and	hyperlipidemia.	Since	CVD	is	the	worldwide	leading	cause	of	death	and	results	in	a	huge	burden	of	mortality	and	morbidity,	statins	are	among	the	most	prescribed	drugs	in	Western	countries	[18].	Although	 they	 are	 generally	 well	 tolerated,	 clinical	 observations	 suggest	 that	statin	exposure	may	exhibit	dose-dependent	skeletal	muscle	damage.		The	 clinical	 spectrum	 of	 myotoxicity	 ranges	 from	 a	 mild	 clinical	 syndrome	consisting	 of	 nonspecific	 myositis	 and	 myalgias	 (occurrence	 of	 1	 -	 5%	 in	patients)	 to	 life-threatening	 rhabdomyolysis	 [2].	 Rhabdomyolysis	 is	 a	 clinical	condition	characterized	by	destruction	of	skeletal	muscle	tissue.	The	most	severe	consequence	of	rhabdomyolysis	is	the	kidney	failure	and	occasionally	death	due	to	 the	 release	 of	 breakdown	 products	 into	 the	 bloodstream,	 leading	 to	accumulation	 of	 them	 in	 kidney	 tubules.	 Rhabdomyolysis	 is	 the	 most	 feared	adverse	 event	 associated	 with	 statin	 therapy	 but	 fortunately	 rare	 for	 statin	monotherapy	 at	 standard	 doses	 [19].	 The	 withdrawal	 of	 cerivastatin	 in	 2001	from	the	market	worldwide	due	to	reports	of	fatal	rhabdomyolysis	(52	deaths	of	drug-related	 rhabdomyolysis	 within	 4	 years),	 generated	 substantial	 alerts	concerning	the	safety	profile	of	the	available	statins	[20].	Graham	et	al.	showed	a	low	incidence	of	rhabdomyolysis	(0.44	in	10.000	patient	years)	for	monotherapy	with	 atorvastatin,	 pravastatin	 or	 simvastatin.	 However,	 adverse	 events	 have	 a	dramatic	 clinical	 relevance	 due	 to	 their	 impact	 on	 quality	 of	 life	 and	 reduce	compliance	of	millions	of	people	taking	statins	every	day	[19].		For	all	these	reasons,	it	is	a	matter	of	great	urgency	to	elucidate	the	mechanisms	by	which	statins	lead	to	side	effects.			1.2	Role	of	pharmacokinetics	and	predisposing	factors	in	statin-induced	myopathy	Myopathies	 are	 associated	 with	 all	 statins	 even	 though	 some	 statins	 have	 a	higher	 risk	 [21].	 Side	 effects	 are	 usually	 dose-dependent.	 Therefore,	pharmacokinetic	 properties	 and	 any	 factor	 (i.e.	 polymorphisms	 or	 drug-	 drug	interactions)	that	increases	the	serum	concentration	of	the	drug	may	predispose	
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to	myopathy	[22].	
In	 vitro	 and	 in	 vivo	 experiments	 suggest	 that	 lipophilic	 statins	 (such	 as	simvastatin,	 lovastatin,	 atorvastatin,	 pitavastatin	 and	 cerivastatin)	 are	 more	likely	 to	 affect	 the	 skeletal	 muscle	 than	 the	 hydrophilic	 statins	 (such	 as	pravastatin,	 rosuvastatin,	 and	 fluvastatin)	 [7]	 [23].	 Lipophilic	 compounds,	indeed,	 tend	 to	 achieve	 higher	 levels	 of	 exposure	 in	 non-hepatic	 tissues	 (e.g.	muscle),	 since	 they	 penetrate	 into	 peripheral	 tissues	 by	 passive	 diffusion	enhancing	 their	 potential	 for	 myotoxic	 effects	 [24].	 Moreover,	 they	 undergo	hepatic	 metabolism	 via	 the	 cytochrome	 P450	 (CYP450)	 system	 which	 makes	them	more	subjected	to	drug-drug	interaction	[7].	In	 contrast,	 hydrophilic	 statins	 tend	 to	 be	 more	 hepatoselective	 since	 they	depends	on	an	active	transport	process	to	enter	the	hepatocytes	and	exert	their	effects.	 Moreover,	 they	 are	 minimally	 metabolized	 by	 the	 cytochrome	 P450	enzyme	 system	 before	 elimination,	 therefore,	 they	 are	 less	 involved	 in	 any	clinically	 relevant	 drug-drug	 interactions	 with	 agents	 that	 induce	 or	 inhibit	CYP450	isoenzymes	[6].	Possible	 pharmacokinetic	 interactions	 of	 statins	 with	 other	 drugs	 deserve	particular	attention.	Because	statins	are	prescribed	on	a	 long-term	basis,	many	patients	might	 receive	 pharmacological	 treatments	 for	 concomitant	 conditions	during	the	course	of	statin	use	[25].	Moreover,	all	statins,	except	pravastatin,	are	metabolized	 by	 CYP450	 isoenzymes	 in	 the	 liver	 [26].	 Three	 commonly	prescribed	statins	(simvastatin,	 lovastatin	and	atorvastatin)	are	metabolized	by	CYP3A4	 [27].	 CYP3A4	 is	 the	 most	 important	 CYP	 isoenzymes	 for	 drug	metabolism,	it	metabolizes	more	than	50%	of	prescribed	drugs,	leading	to	a	huge	risk	of	drug-drug	interactions	[28].	 Both	 CYP450	 inhibitors	 and	 inducers	 play	 an	 important	 role	 in	 disposition	 of	statin,	 in	 terms	 of	 their	 plasma	 levels	 and	 the	 risk	 of	 statin-induced	 adverse	effects	[26].	Neuvonen	et	al.	[29]	reported	that	simvastatin-associated	muscle	disorders	were			6-fold	higher	when	patients	were	taking	CYP3A4	inhibitors	at	the	same	time	but,	there	were	no	change	in	patients	taking	CYP3A4	inhibitors	in	combination	with	pravastatin	(which	is	not	metabolized	by	CYP3A4). Cytochrome	P450	inhibitors	are	agents	that	inhibit	the	hepatic	enzymes,	leading	
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to	 increased	plasma	 levels	of	 statins	and	greater	 risk	of	 adverse	effects.	While,	cytochrome	P450	inducers	are	agents	that	 induce	the	hepatic	enzymes,	 leading	to	decreased	plasma	levels	of	statins	and	a	subsequent	decreased	bioavailability	of	statin	[30].	In	table	1	are	reported	the	most	common	inhibitors	and	inducers	which	influence	statin	metabolism.	Statin-fibrate	 combination	 therapy	deserves	particular	precautionary	warnings	because	 myopathy	 can	 occur	 with	 either	 drug	 alone,	 and	 the	 effects	 may	 be	additive	[20]	[4].	Shek	 et	 al.	 showed	 that	 a	 co-administration	 of	 statin	 and	 fibrate	 increases	 the	risk	 of	 myopathy	 associated	 with	 CK	 elevations	 with	 an	 incidence	 of	approximately	 0.12%.	Although	 all	 fibrates	 have	been	 associated	with	 cases	 of	CK	elevations	and	myopathy	in	combination	with	statins,	the	risk	of	developing	myopathy	 and	 rhabdomyolysis	 with	 gemfibrozil	 was	 10-	 to	 15-fold	 higher	compared	 to	 other	 fibrates.	 The	 leading	 cause	 of	 this	 higher	 toxicity	 is	 that	gemfibrozil	 exhibits	 greater	 inhibitory	 potency	 towards	 specific	 CYP450	 and	UDP-glucuronosyltransferase	 (UGT)	 isoenzymes	 that	 leads	 to	 a	 reduced	 statin	clearance	[31]	[32]	[33].	Not	 only	 the	 concomitant	 administration	 of	 lipid-lowering	 agents,	 but	 also	genetic	 factors	 and	 drug	 transporter	 expression	 are	 variables	 that	 could	 affect	the	concentration-effect	relationship.		It	 has	 been	 demonstrated	 that	 the	 organic	 anion	 transporting	 polypeptide	(OATP)	 is	 important	 for	 the	 hepatic	 uptake	 of	 hydrophilic	 statins	 [22].	 The	hepatic	transporter	OATP1B1	is	the	main	transporter	of	statins	into	the	liver.		A	single	nucleotide	polymorphism	in	the	SLCO1B1	gene	that	encodes	the	OATP1B1	leads	to	decreased	hepatic	uptake,	increased	plasma	statin	levels	which,	in	turn,	causes	myopathy	[34]	[35].	
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	 Statins	 Inhibitors	 	Inducers		
CYP3A4	
	Simvastatin,	lovastatin,	atorvastatin	
	Ketoconazole,	itraconazole,	fluconazole,		erythromycin,	clarithromycin,	tricyclic	 anti-depressants,	nefazodone,	 venlafaxine,	fluvoxamine,	 fluoxetine,	sertraline,		cyclosporine	A,		tacrolimus,		mibefradil,		diltiazem,		verapamil,		protease	 	 inhibitors,	midazolam,		corticosteroids,		grapefruit	juice,		tamoxifen,	 and	amiodarone		
	Barbiturates,	phenytoin,	phenobarbital,	barbiturates,	rifampin,	dexamethasone,	cyclophosphamide,	carbamazepine,	omeprazole,	troglitazone	
CYP2C9	
	Fluvastatin,	rosuvastatin	
	Ketoconazole,		fluconazole,		sulfaphenazole	
	Rifampin,	 phenobarbital,	phenytoin,	troglitazone		
Table	1:	list	of	the	most	common	inhibitors	and	inducers	or	CYP	involved	in	statin	
metabolism		
	 		
	 13	
2	Potential	mechanisms	of	statin-induced	myopathy	
In	 the	 recent	 years	 enormous	 effort	 has	 been	made	 to	 uncover	 the	molecular	mechanisms	 of	 statin-induced	myotoxicity	 and	 several	 causes	 are	 discussed	 in	literature	[21]	[36]	[11].		2.1	Inhibition	of	the	mevalonate	pathway	The	 most	 likely	 reason	 for	 adverse	 drug	 reactions	 associated	 with	 statins	 is	linked	 to	 their	mechanism	 of	 action	 [37]	 [26].	 The	 inhibition	 of	 the	 HMG-CoA	reductase	 leads	 not	 only	 to	 a	 blockage	 of	 cholesterol	 synthesis	 but	 also	 to	 a	reduced	 production	 of	 all	 intermediates	 such	 as	 mevalonate	 and	 various	isoprenoid	derivatives	(Fig.	1)	enabling	statins	to	affect	many	cellular	processes	[38].	Masters	et	al.	showed	that	the	replacement	of	mevalonate	abolished	the	changes	associated	with	statin	treatment	[24].	Whereas	the	downstream	inhibition	of	the	enzymes	squalene	 synthase	or	 squalene	epoxidase	does	not	 cause	myotoxycity	[39]	[40].	Taken	together,	these	findings	suggest	that	statin-induced	myotoxicity	is	 most	 likely	 due	 to	 the	 reduction	 in	 the	 synthesis	 of	 crucial	 intermediary	isoprenoid	 derivatives	 such	 as	 geranyl	 pyrophosphate	 (GPP)	 and	 farnesyl	pyrophosphate	(FPP)	and	not	 to	 the	reduction	 in	cholesterol	synthesis.	 Indeed,	GPP	and	FPP	are	responsible	for	the	prenylation	of	various	proteins	essential	in	a	 variety	 of	 cellular	 signaling	 pathways,	 transportation,	 cell	 growth	 and	transformation	 processes	 that	 enhance	 cell-membrane	 integrity	 and	 support	intracellular	metabolic	pathways		[41-43].	Evidence	for	the	involvement	of	dysprenylation	in	statin-induced	myotoxicity	is	provided	 by	 studies	 that	 revealed	 that	 the	 addition	 of	 geranylgeraniol	 (GGOH)	rescues	statin-treated	cells	from	apoptosis	[41].	Moreover,	statin-related	inhibition	of	dolichol	synthesis	impairs	N-glycosylation	of	 cell	 surface	proteins	 such	as	 the	 insulin	 like	growth	 factor	 -1	 receptor	 (IGF-1R).	 Correct	 α	 –subunit	 glycosylation	 is	 essential	 for	 the	 cleavage	 of	 the	 pro-receptor	and,	 therefore,	 for	 the	 formation	of	mature	 functional	 IGF-1R	[44,	45]	[46].	Coenzyme	 Q10	 (CoQ10),	 also	 known	 as	 ubiquinone,	 is	 synthesized	 via	
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mevalonate	pathway.	CoQ10	 is	 a	 lipophilic	 component	of	 the	 respiratory	 chain	that	transfers	electrons	from	complexes	I	and	II	to	complex	III.	CoQ10	has	a	key	role	in	the	oxidative	phosphorylation	in	mitochondria	and	consequently	in	ATP	production.	 Furthermore,	 it	 has	 antioxidant	 properties	 and	 serves	 as	 a	membrane	 stabilizer.	 Due	 to	 the	 central	 role	 of	 ubiquinone	 in	 the	 respiratory	chain,	 it	 was	 hypothesized	 that	 its	 deficit	 mediates	 statin-induced	 myopathy.	However,	no	direct	association	between	decreased	CoQ10	levels	in	myocytes	and	myopathy	 has	 ever	 been	 demonstrated	 in	 any	 human	 or	 animal	 study	 [3,	 47].		Moreover,	oral	CoQ10	supplementation	did	not	prevent	the	risk	of	statin-related	myopathy	[48].		2.2	Direct	effects	on	the	mitochondrial	electron	transport	chain		The	 mitochondria	 electron	 transport	 chain	 (ETC)	 is	 composed	 of	 four	multiprotein	complexes	and	it	 is	an	essential	for	the	cellular	energy	production	(Fig.	6).		Via	a	series	of	redox	reactions,	electrons	are	transferred	from	an	electron	donor	(NADH	 or	 QH2)	 to	 a	 terminal	 electron	 acceptor	 (O2).	 These	 redox	 reactions	release	energy	which	 is	used	 to	actively	pump	protons	 from	the	mitochondrial	matrix	 into	 the	 intermembrane	space	 through	 three	proton	pumps	 (Complex	 I,	III	 and	 IV).	 This	 generates	 a	 proton	 gradient	 that	 drives	 ATP	 synthesis	 via	oxidative	phosphorylation	at	the	ATP	synthase	[49].		Independent	 studies	 observed	 vacuolization	 of	 mitochondria	 and	 disrupted	cristae	pointing	to	a	primary	involvement	of	mitochondria	in	the	pathogenesis	of	statin-induced	muscle	atrophy	[50,	51].	Schick	et	al.	detected	a	decrease	 in	mitochondrial	DNA	in	patients	 treated	with	high	 doses	 of	 simvastatin	 again	 indicating	 the	 involvement	 of	 a	mitochondrial	damage	 [52].	 In	 a	 clinical	 setting,	 patients	 under	 statin	 therapy	 emerged	 a	significantly	 increased	 serum	 lactate/pyruvate	 ratio,	 which	 points	 to	 a	mitochondrial	 dysfunction	 accompanied	 by	 a	 compensatory	 increase	 in	glycolysis	[53].	Several	 studies	 revealed	 that	 statins	 directly	 inhibit	 complexes	 of	 the	 electron	transport	chain	(ETC)	[54]	[55]	[56].	The	inhibition	occurs	immediately	and	on	
	 		
	 15	
isolated	 mitochondria,	 suggesting	 that	 statins	 have	 a	 direct	 effect	 on	mitochondria	[57]	[58].		Since	 mitochondria	 are	 involved	 not	 only	 with	 bioenergetics	 but	 also	 with	oxidative	 damage	 and	 apoptosis,	 a	 direct	 inhibition	 of	 the	 ETC	 would	 have	dramatic	effects:	energy	levels	would	drop	down,	mitochondrial	integrity	would	be	compromised,	and	apoptosis	triggered	[58].		However,	it	is	worth	to	highlight	that	many	studies	investigating	the	toxic	effect	on	 mitochondrial	 ETC	 use	 very	 high	 concentrations	 of	 statins [59]. Whether	localized	 concentrations	 of	 statins	 could	 reach	 levels	 high	 enough	 in	 the	mitochondria	of	patients	is	still	a	question	of	debate	[60].  Nevertheless,	 the	 effect	 of	 statins	 on	 mitochondria	 in	 patients	 with	 genetic	variations	 in	 the	 complexes	 or	 transporters	may	 increase	 the	 susceptibility	 to	muscle	symptoms	[60].	Further	 evidence	 of	 a	 direct	 effect	 of	 statins	 on	 the	 mitochondrial	 ETC	 is	provided	by	Sirvent	et	al.	[61].		They	showed	that	statin	treatment	affects	cellular	Ca2+	homeostasis	by	inducing	an	efflux	of	Ca2+.		They	suggested	that	this	is	caused	maily	 by	 lipophilic	 statins	 which	 are	 able	 to	 diffuse	 into	 muscle	 fibers	 and	directly	inhibit	one	or	more	complexes	of	the	mitochondrial	ETC.		Altered	 Ca2+	homeostasis	 in	 the	muscles	 triggers	 apoptosis	 via	 distinct	 targets,	leading	to	muscle	dysfunction	and	dysregulation.	For	instance,	activation	of	Ca2+-dependent	 protein	 phosphatase	 such	 as	 calcineurin	 leads	 to	 altered	 gene	transcription,	activation	of	Ca2+-dependent	endonucleases	causes	apoptotic	DNA	degradation	 or	 activation	 of	 Ca2+-dependent	proteases	 such	 as	 calpain	 induces		apoptosis	[62].	
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Figure	 6.	 The	 mitochondrial	 respiratory	 chain.	 	 Electrons	 enter	 the	respiratory	 chain	 via	 the	 complex	 I	 and	 are	 transferred	 to	 ubiquinone	 (Q).	Additional	electrons	are	delivered	from	the	oxidation	of	complex	II	via	FADH2	and	 are	 also	 transferred	 into	 the	 ubiquinone	 pool.	 The	 Q-cycle	 contributes	electrons	 to	 the	 cytochrome	 c	 via	 complex	 III.	 Complex	 IV	 catalyzes	 the	reduction	 of	 oxygen	 to	 water.	 The	 electron	 transport	 chain	 and	 the	 ATP	production	are	coupled	by	a	proton	gradient	across	 the	 inner	mitochondrial	membrane.	 This	 electrochemical	 gradient	 is	 used	 by	 the	 ATP	 synthase	 to	generate	ATP	via	oxidative	phosphorylation.	
		
3	The	insulin-like	growth	factor	1	pathway	
The	insulin-like	growth	factor	1		(IGF-1)	is	a	70	amino	acid	peptide	with	a	high	degree	of	sequence	homology	to	insulin	[63].	IGF-1	pathway	provides	a	potent	proliferative	 signaling	 system	 that	 stimulates	growth	and	differentiation	in	many	different	cell	types	and	it	is	considered	one	of	the	most	important	signaling	pathway	for	inducing	skeletal	muscle	hypertrophy	and	cell	survival	[9]	(Fig.	7).	IGF-1	 signals	 primarily	 through	 the	 IGF-1	 receptor	 (IGF-1R),	 a	 tyrosine	 kinase	receptor	that	consists	of	α2β2	heterotetramers	held	together	by	disulfide	bridges	[64].		
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When	IGF-1	binds	to	the	extracellular	α	subunits	of	the	receptor,	the	intracellular	
β	subunits	undergo	a	conformational	change	leading	to	the	autophosphorylation	of	 intracellular	 tyrosine.	 This	 event	 causes	 an	 activation	 of	 phosphorylation	cascade	of	several	substrates,	 including	the	 insulin	receptor	substrate	 family	of	proteins	 (such	 as	 Insulin	 receptor	 substrate	 1	 and	 others)	 [65].	 Once	phosphorylated,	 these	 docking	 proteins	 activate	 downstream	 intracellular	signaling	through	the	cytoplasmic	phosphatidylinositol	3-kinase	(PI3K)	pathway	leading	to	a	subsequent	phosphorylation	and	activation	of	AKT.		AKT	is	a	serine-threonine	protein	kinase	that	plays	a	key	role	in	controlling	vital	cellular	 functions	 such	 as	 cell	 survival/apoptosis,	 cell	 cycle	 progression	 and	proliferation	[66].		AKT	 inhibits	 protein	 degradation	 by	 phosphorylating	 and,	 thus	 inhibiting,	 the	nuclear	translocation	of	the	transcription	factors	Forkhead	box	O	(FoxO)	family	[67]	 [68].	 FoxO	 factors	 are	 required	 for	 the	 transcriptional	 regulation	 of	 the	ubiquitin	 ligases	 atrogin-1,	 also	 called	 muscle	 atrophy	 F-box	 (MAFbx)	 and	muscle	ring	finger	1	(MuRF-1),	 leading	to	the	ubiquitylation	of	muscle	proteins	and	their	subsequent	degradation	via	the	proteasome	[69]	[70].		Furthermore,	 AKT	 stimulates	 protein	 synthesis	 via	 phosphorylation	 of	 the	mammalian	 target	 of	 rapamycin	 (mTOR).	 In	 turn,	 mTOR	 mediates	phosphorylation	 and	 activation	 of	 S6	 kinase	 (S6K),	 and	 in	 parallel,	phosphorylation	and	inactivation	of	4E-BP1,	a	repressor	of	translation	initiation.		S6K	 directly	 phosphorylates	 the	 40S	 ribosomal	 protein	 S6,	 increasing	 the	translation	 of	 mRNA	 while,	 phosphorylated	 4E-BP1	 activates	 eukaryotic	translation	 initiation	 factor	 4E	 (eIF4E)	which	 binds	 an	mRNA	 cap	 and	 triggers	the	translation	[71]	[72]	[73].	In	 addition,	AKT	promotes	 cell	 survival	 regulating	 several	proteins	 involved	 in	apoptosis.		The	primary	 target	 is	Bad,	a	pro-apoptotic	protein	 that	 interacts	with	 the	anti-apoptotic	 Bcl-2	 at	 the	mitochondrial	membrane.	 Upon	 phosphorylation	 on	 Ser	136	by	AKT,	BAD	dissociates	from	Bcl-2	and	its	pro-apoptotic	function	is	blocked	[74]	[75]	[76].		Moreover,	 AKT	 promotes	 survival	 also	 through	 inactivating	 caspases,	 thus	preventing	the	initiation	of	the	pro-apoptotic	machinery	[77]	[78]	[79].		
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Fig.	7.	A	simplified	scheme	of	the	IGF-1	pathway.		 	
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3.1	What	is	the	link	between	the	IGF-1	signaling	pathway	and	statin-induced	toxicity?	Recently	Mullen	et	al.	revealed	a	decrease	in	AKT	phosphorylation	hence	leading	to	the	induction	of	E3	ubiquitin	ligase	atrogin-1	during	statin-treatment	in	vitro.	As	a	consequence,	skeletal	muscle	fibers	undergo	to	cell	death	[56].	Reduced	 AKT	 phosphorylation	 leads	 to	 an	 increased	 nuclear	 translocation	 of	FoxO	 transcription	 factors	 and	 subsequent	 upregulation	 of	 atrophy	 markers	MuRF-1	and	MAFbx	[80].	 In	the	case	of	FoxO3,	activation	was	demonstrated	to	be	 sufficient	 to	 induce	 atrophy	 [80],	 a	 finding,	 which	 was	 subsequently	supported	 by	 the	 atrophic	 phenotype	 induced	 by	 the	 transgenic	 expression	 of	FoxO1	[81].	In	 addition,	 in	 vitro	 studies	 demonstrated	 that	 the	 ubiquitin-proteasome	proteolytic	 genes,	 MAFbx	 and	 MuRF-1,	 are	 responsible	 for	 promoting	 protein	degradation	in	dexamethasone-induced	atrophy	in	differentiated	myotubes	[82]. Similarly,	 Hanai	 et	 al.	 highlighted	 the	 importance	 of	 MAFbx	 in	 statin-induced	myopathy.	They	showed	that	atrogin-1	knockout	mice	and	knockdown	zebrafish	are	resistant	to	statin-induced	myopathy	[83].		Conversely,	genetic	activation	of	AKT	was	shown	to	be	able	to	block	the	atrophy-associated	upregulation	in	MAFbx	and	MuRF-1	transcription	[9]	by	inactivating	FoxO	transcription	factors	[80]	[9].		IGF-1	 is	 a	 hypertrophy-inducer	 agent	 [84].	 It	 increases	 muscle	 mass	 by	stimulating	 the	 AKT	 pathway	 [10],	 resulting	 in	 the	 downstream	 activation	 of	targets	which	are	required	for	protein	synthesis	[79]	and	inactivation	of	targets	which	are	involved	in	protein	degradation	[9].		IGF-1	treatment	has	an	integral	role	in	antagonizing	[70]	[9]	[65]	or	attenuating	settings	 of	 skeletal	 muscle	 atrophy	 [85]	 acting	 through	 the	 AKT	 signaling	pathway	[9,	63].		Taken	 together,	 these	 findings	 lead	 to	 the	 conclusion	 that	 dysregulation	of	 the					IGF-1/AKT	pathway	may	be	a	key	step	in	statin-induced	muscle	damage.		However,	 the	 precise	 mechanism,	 of	 how	 statins	 interfere	 with	 IGF-1/AKT	signaling	 hence	 leading	 to	 the	 induction	 of	 MAFbx	 in	 muscle	 cells	 is	 still	 not	solved.		
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As	mentioned	previously,	 statins	reduce	dolichol	production,	which	 is	 required	for	 the	N-	glycosylation	of	 the	 IGF-1R	 [86].	A	decrease	 in	mature	 IGF-1R	could	lead	 to	 reduced	 AKT	 phosphylation,	 increased	 nuclear	 translocation	 of	 FoxO1	and	FoxO3a,	and	an	upregulation	in	MAFbx.		In	 addition,	 the	 dysprenylation	 of	 small	 GTPases,	 that	 are	 crucial	 in	 many	signaling	pathways	[86]	and	could	also		be	involved	in	IGF-1/AKT	signaling	[87].		
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Aims	
This	thesis	has	three	main	aims.	Firstly,	we	aimed	to	uncover	the	effect	of	three	common	 prescribed	 statins,	 simvastatin,	 atorvastatin	 and	 rosuvastatin,	 on	skeletal	muscle.	As	simvastatin	is	known	to	be	toxic	on	C2C12	myotubes	and	to	negatively	 regulate	 the	 AKT	 signaling	 pathway	 [56],	 it	 was	 our	 main	 goal	 to	understand	whether	the	AKT	signaling	cascade	plays	a	role	in	the	statin-induced	myotoxicity.	 For	 this	 reason,	 we	 conducted	 our	 experiments	 on	 myotubes	derived	from	the	C2C12	skeletal	muscle	cell	 line,	and	we	induced	them	with	10	µM	or	50	µM	of	 simvastatin,	atorvastatin	or	 rosuvastatin.	We	 initially	analyzed	differential	 patterns	 of	 protein	 involved	 in	 the	 AKT	 signaling	 pathway,	 and	looked	 for	 differences	 in	 these	 components.	 Then,	 we	 correlated	 the	 protein	expression	pattern	with	the	atrophic	effects.	This	was	the	first	time	such	analysis	would	have	been	performed,	and	would	point	to	possible	mechanisms	for	statin-induced	skeletal	muscle	toxicity.	The	 second	 aim	 of	 this	 thesis	 was	 to	 expand	 our	 previous	 findings	 by	investigating	 whether	 IGF-1	 could	 reduce	 or	 block	 the	 simvastatin-induced	toxicity.	 Indeed,	 IGF-1	has	a	major	anabolic	effect	 in	various	cell	 lines	 [70,	88].	Moreover,	 IGF-1/AKT	pathway	 is	 a	 central	player	 regulating	muscle	mass	as	 it	activates	protein	 synthesis	 and	 inhibits	protein	degradation	 [10].	We	aimed	 to	uncover	 whether	 the	 activation	 of	 IGF-1/AKT	 pathway	 is	 sufficient	 to	 have	 a	prevention	 of	 statin-induced	myotoxicity	 in	 C2C12	myotubes.	 This	 study	has	 a	potential	 impact	 on	 the	 discovery	 of	 new	 therapeutic	 avenue	 to	 treat	 statin-induced	toxicity.	The	 final	aim	of	 this	 thesis	was	to	 look	 for	 toxicity	of	statins	 in	cardiac	muscle.	This	topic	has	a	great	relevance	since	the	prevention	of	cardiovascular	disease	is	the	primary	reason	for	prescribing	statins.	Statins	have	been	reported	to	inhibit	mitochondrial	 function	 in	 various	 cell	 lines	 [37]	 and	 induce	 skeletal	 muscle	atrophy	 [21,	 56].	 We	 shed	 light	 on	 whether	 simvastatin	 affects	 cardiac	mitochondria	leading	to	cardiac	atrophy.	We	used	in	vivo	and	in	vitro	models	to	present,	 for	 the	 first	 time,	 evidence	 of	 simvastatin-induced	 toxicity	 in	
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cardiomyocytes	 linked	to	a	bioenergetic	 failure.	This	data	opens	new	questions	concerning	statin	safety	and,	 in	 the	same	time,	might	be	an	explanation	 for	 the	observed	 idiosyncratic	 toxicity,	which	 affects	 only	 a	 small	minority	 of	 patients	taking	statins.			
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Statins are drugs that lower blood cholesterol levels and reduce cardiovascularmorbidity andmortality. They are
generally well-tolerated, but myopathy is a potentially severe adverse reaction of these compounds. The mech-
anisms by which statins induce myotoxicity are not completely understood, but may be related to inhibition of
the AKT signaling pathway. The current studies were performed to explore the down-stream effects of the
statin-associated inhibition of AKT within the AKT signaling pathway and on myocyte biology and morphology
in C2C12myotubes and inmice in vivo.We exposed C2C12myotubes to 10 μMor 50 μMsimvastatin, atorvastatin
or rosuvastatin for 24 h. Simvastatin and atorvastatin inhibited AKT phosphorylation andwere cytotoxic starting
at 10 μM,whereas similar effectswere observed for rosuvastatin at 50 μM. Inhibition of AKT phosphorylationwas
associated with impaired phosphorylation of S6 kinase, ribosomal protein S6, 4E-binding protein 1 and FoxO3a,
resulting in reduced protein synthesis, accelerated myoﬁbrillar degradation and atrophy of C2C12 myotubes.
Furthermore, impaired AKT phosphorylation was associated with activation of caspases and PARP, reﬂecting
induction of apoptosis. Similar ﬁndings were detected in skeletal muscle of mice treated orally with
5 mg/kg/day simvastatin for 3 weeks. In conclusion, this study highlights the importance of the AKT/mTOR sig-
naling pathway in statin-induced myotoxicity and reveals potential drug targets for treatment of patients with
statin-associated myopathies.
© 2015 Elsevier B.V. All rights reserved.
1. Introduction
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibi-
tors) are currently the most often prescribed and the most effective
cholesterol-lowering drugs. They are generally well-tolerated but can
rarely be associatedwith potentially severe adverse reactions, particular-
ly on skeletal muscle [1,2]. Statin-associated muscle injuries vary from
mild myopathy to potentially lethal rhabdomyolysis, a condition charac-
terized by massive destruction of muscle ﬁbers and release of their con-
tents into the bloodstream [3,4]. While muscle pain affects up to 20% of
statin users [5], more severe adverse muscular reactions are much rarer
[1,2]. In a large study in theUSA, the incidence of rhabdomyolysis leading
to hospitalization was zero for pravastatin, approximately 0.5 per
10,000 person-years for simvastatin and atorvastatin and 5.3 per
10,000 person-years for cerivastatin [6]. In combination with a ﬁbrate,
the incidence rose by a factor of 10 or more.
While a high exposure to statins is a clearly established risk factor for
statin-associatedmyopathy [1,2,7], the molecular mechanisms leading to
muscle damage, in particular rhabdomyolysis, in patients treated with
statins are less clear [3]. Different factors could play a role; for example
impairedmitochondrial function [8,9], inductionof skeletalmuscle break-
down due to increased expression of atrogin-1/MaFbx [10], reduction of
skeletal muscle protein synthesis [11], inhibition of small GTPases due
to impaired prenylation [12] and/or impaired creatine synthesis [13].
Previous work from our group suggested that simvastatin-induced
myotoxicity might be related to inhibition of the phosphorylation and
thereby activation of AKT [14]. As shown in Fig. 1, the AKT signaling path-
way is essential formuscle growthduring development and regeneration.
AKT functions as a key regulator of both protein synthesis and degrada-
tion by activating the protein kinase mammalian target of rapamycin
(mTOR) [15] and by inhibiting forkhead box O (FoxO) transcription fac-
tors [16]. Moreover, AKT is directly involved in the regulation of cell sur-
vival through the suppression of apoptosis by blocking the activation of
caspases [17].
Activation of mTOR by AKT leads to phosphorylation of the ribosomal
protein S6 kinase (S6K) at Thr 389,which phosphorylates and thereby ac-
tivates the ribosomal protein S6 (rpS6) [18]. Furthermore, activation of
Biochimica et Biophysica Acta 1853 (2015) 1841–1849
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mTOR leads to phosphorylation of the eukaryotic translation initiation
factor 4E binding protein 1 (4E-BP1), thereby disrupting its interaction
with eIF4E and making eIF4E available for mRNA translation [19]. Im-
paired activation of mTOR is therefore expected to reduce protein
synthesis.
Forkheadmembers of theO class (FoxO) forma family of transcription
factors involved in protein breakdown and apoptosis. Several insults such
as apoptosis, oxidative stress and/or cytokine release activate FoxO3a by
dephosphorylation, which is followed by nuclear translocation of the de-
phosphorylated protein [20]. Activation of Foxo3a is associatedwithmus-
cle atrophy, since nuclear translocation of FoxO3a triggers the expression
of mediators of proteolysis such as muscle RING-ﬁnger protein-1 (MuRF-
1) and muscle atrophy F-box (atrogin-1/MaFbx) [21,22].
Taking into account our previous observations regarding the effect of
simvastatin on AKT activation [14] and the central role of AKT for skel-
etal muscle protein metabolism and integrity [15–17], the principle
aims of the current study were 1. to investigate whether inhibition of
the phosphorylation of AKT is speciﬁc for simvastatin or can also ob-
served for other statins, 2. to investigate the downstream effects of the
inhibition of AKT on target proteins involved in apoptosis, protein deg-
radation and protein synthesis, and 3. to demonstrate that these effects
cannot only be shown in vitro in cultured myotubes but also in vivo in
mice treated with simvastatin.
2. Materials and methods
2.1. Chemicals
Simvastatin lactone (Sigma-Aldrich, St. Louis, MO, USA) was con-
verted into the active acid following the protocol of Bogman et al. [23].
We prepared stock solutions (10mMand 50mM) in dimethylsulfoxide
(DMSO) for simvastatin and in water for rosuvastatin and atorvastatin.
We stored them at −20 °C. All chemicals were supplied by Sigma-
Aldrich (St. Louis, MO, USA), except where indicated.
2.2. Cell lines and cell culture
C2C12 myoblasts were originally obtained from the American Type
Culture Collection (ATCC) and kindly provided by Novartis (Basel,
CH). We grew cells at 37 °C and 5% CO2 in a humidiﬁed cell culture in-
cubator and we passaged them using trypsin. We initially seeded
150,000 myoblasts per well in a 6-well plate, and grew them for
2 days in growth medium consisting of high glucose (4.5 g/L)
Dulbecco's Modiﬁed Eagle Medium (DMEM) containing GlutaMAX
(Invitrogen, Basel, Switzerland) and 10% heat-inactivated fetal bovine
serum (Gibco, Paisley, UK). Afterwards, we induced cell differentiation
using high glucose DMEM supplemented with 2% horse serum (Gibco,
Paisley, UK) for 3 days. A morphological analysis of the cell cultures
showed that 83±3% of the nuclei were located in tubes. Then,we incu-
bated the cell cultures in serum-free DMEM (Invitrogen, Basel,
Switzerland) for 24 h before the addition of the test compounds. Since
simvastatin had been dissolved in DMSO, we used control incubations
containing 0.1% DMSO. This DMSO concentration has been shown not
to be cytotoxic [24]. After 24 h treatment, we collected the cells to ex-
amine the expression of genes and activation of proteins of interest.
2.3. Animals
The animal studywas approved by the cantonal veterinary authority
(License 2659) and was performed in accordance with the guidelines
FoxO
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MuRF1/MAFbx
Protein degradation
S6K
Caspase 9
Caspase 3
Protein Synthesis Apoptosis
PARP
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Growth factorsCytokines
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transmitters, 
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Cytoplasmic domain 
rpS6
4E-BP1
Fig. 1. Schematic representation of the AKT/mTOR signaling pathway. Upon activation by hormones, cytokines or growth factors, AKT translocates to the plasma membrane and is
phosphorylated on Ser 473 and on Thr 308. Once activated, AKT phosphorylates downstreamcytosolic and nuclear effectors inducing protein synthesis and blocking apoptosis and protein
degradation.
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from Directive 2010/63/EU of the European Parliament on the protec-
tion of animals used for scientiﬁc purposes. Seven weeks old male
C57BL/6 mice were obtained from Charles River Laboratories (Sutzfeld,
Germany) and were housed under controlled conditions at a 12 h/
12 h light/dark cycle with free access to water and a standard pellet
chow. After 7 days of acclimatization, the mice were randomly divided
into two groups of eight animals. We treated the mice either with sim-
vastatin (5 mg/kg/day) dissolved in water (SMV group) or water (CTL
group) by oral gavage for 3 weeks. The body weight of the animals
and food intake were recorded every 2 days.
2.4. Sample collection
After 21 days of treatment,micewere anesthetizedwith an intraper-
itoneal application of ketamine (100 mg/kg) and xylazine (10 mg/kg).
Gastrocnemius muscle samples were frozen in liquid nitrogen immedi-
ately after excision. Since the tissue samples were obtained from living
animals (mice were anesthetized), the time between sampling and
freezing was only few seconds. Samples were kept at −80 °C until
analysis.
2.5. Cytotoxicity assay
Weused the ToxiLight BioAssay Kit (Lonza, Basel, Switzerland) to in-
vestigate the cytotoxicity of the compounds on C2C12 myotubes. The
release of adenylate kinase was measured according to the
manufacturer's manual using luminescence with a Tecan M200 Pro In-
ﬁnity plate reader (Männedorf, Switzerland).
2.6. Cell lysis and immunoblotting
After incubationwith different compounds, we homogenized C2C12
myotubes in Phosphosafe buffer (EMDMillipore, USA). Then,we centri-
fuged the samples at 1600 ×g for 10 min at 4 °C. We then collected the
supernatant and determined the protein content in each supernatant
using the BCA Protein Assay Kit (Pierce, Thermo Scientiﬁc, Rockford,
USA). Supernatants were applied on 4–12% Bis–Tris polyacrylamide
gels (Invitrogen, Basel, Switzerland) for protein separation and run
under reducing conditions. After separation, proteins were transferred
to polyvinylidendiﬂuoride membranes (EMD Millipore, Massachusetts,
USA).Weblocked themembraneswith 5%nonfat drymilk in phosphate
buffered saline (PBS) (Gibco, Paisley, UK) containing 0.1% Tween-20
(Sigma-Aldrich, MO, USA) (PBS-T) for 1 h at room temperature before
incubation overnight with the primary antibody (Cell Signaling Tech-
nology, USA) diluted 1:1000 in blocking buffer. The day after, we incu-
bated the blots for 1 h with the secondary antibody (Santa Cruz
Biotechnology, USA) diluted 1:2000 in 5% nonfat milk in PBS-T. Then,
we washed the membranes and developed the immunoreactive bands
using enhanced chemiluminescence (GE Healthcare, Buckinghamshire,
United Kingdom). Chemiluminescent imageswere scanned using anHP
Scanjet 8300 (Hewlett-Packard Co., Palo Alto, CA) and band intensities
of the scanned images were analyzed using the National Institutes of
Health Image J program (version 1.41). To correct for loading differ-
ences, the scanning units obtained for the test proteins were divided
by the scanning units obtained for either the respective total protein
or for housekeeping protein GAPDH.
The ELISA for the quantiﬁcation of S6K phosphorylation at T389was
obtained from Abcam, Cambridge, UK (p70S6K pT389 PhosphoTracer
ELISA Kit). The ELISA was performed exactly using the protocol of the
provider described in the protocol book.
2.7. Real-time polymerase chain reaction (RT-PCR)
We treated C2C12 myotubes with 10 μM and 50 μM of simvastatin,
rosuvastatin or atorvastatin for 24 h. Afterwards, mRNA was extracted
and puriﬁed using the Qiagen RNeasy mini extraction kit (Qiagen,
Hombrechtikon, Switzerland). RNA concentration and integrity were
evaluated with the NanoDrop 2000 (Thermo Scientiﬁc, Wohlen,
Switzerland) and cDNA was synthesized from 10 μg RNA using the
Qiagen omniscript system. We performed the real-time PCR analysis
using SYBR green (Roche Diagnostics, Rotkreuz, Basel). We assessed
mRNA expression for genes associated with muscle atrophy using the
following primers. MAFbx: forward 5′AGTGAGGACCGGCTACTGTG3′
and reverse 5′GATCAAACGTTGCGAATCT3′. MuRF-1: forward 5′CCTG
CAGAGTGACCAAGGA3′ and reverse 5′GGCGTAGAGGGTGTCAAACT3′.
Real time PCR was performed using the ViiA7 software (Life technolo-
gies, Switzerland). We calculated relative quantities of speciﬁcally am-
pliﬁed cDNA with the comparative–threshold cycle method using
GAPDH as the housekeeping gene (forward 5′-CATGGCCTTCCGTGTTCC
TA-3′ and reverse 5′CCTGCTTCACCACCTTCTTGA-3′). Controls for non-
speciﬁc ampliﬁcation were run without reverse transcription.
2.8. Immunostaining and diameter measurement
To analyze changes inmyotube diameter,myotubeswere stained fol-
lowing the protocol of Minetti et al. [25]. Brieﬂy, myotubes were ﬁxed
with 4% PFA (Paraformaldehyde) and permeabilized with 0.2% Triton.
Nonspeciﬁc binding was blocked with goat serum (Gibco, Paisley, UK)
followed by incubation with anti-myosin heavy chain (anti-MHC)
(EMD Millipore, Massachusetts, USA) diluted 1:1000 in PBS and subse-
quently with Alexa ﬂuor 488 (Invitrogen, Basel, Switzerland) diluted
1:2000 in PBS. To measure diameters, we used CellInsight Technology
(Thermo scientiﬁc, Wohlen, Switzerland). The protein content of the
cells was determined as described in Section 2.6.
2.9. Apoptotic DNA fragmentation ELISA
Apoptosis-associated DNA fragmentation was quantiﬁed using the
cell death detection ELISA kit from Roche (Roche Applied Science,
Indianapolis, IN) by assessing the cytosolic histone-associated mono-
and oligo-nucleosomes. Brieﬂy, the extracted nuclei-free cytosolic frac-
tion was used as an antigen source in a sandwich ELISA with a primary
anti-histone mouse monoclonal antibody coated to the microtiter plate
and a second anti-DNA mouse monoclonal antibody coupled to peroxi-
dase. The amount of peroxidase retained in the immunocomplex was
determined photometrically after incubation with 2,2′-azino-di-[3-
ethylbenzthiazoline sulfonate] (ABTS) for 10 min at 20 °C. The change
in color was measured at 405 nm using a Tecan M200 Pro Inﬁnity
plate reader (Männedorf, Switzerland). Measurements were performed
in triplicate with all samples analyzed on the same microtiter plate in
the same setting. The OD readingwas normalized to the protein content
of the incubations.
2.10. Histological analysis of muscle tissue
Muscle samples were frozen in isopentane. Frozen sections were
stained with hematoxylin–eosin. H&E staining photographs were cap-
tured on an Olympus BX61 microscope (Olympus, Hamburg,
Germany). After staining, we selected randommuscle ﬁbers with a dis-
tinct cell membrane and we excluded elongated ﬁbers indicating an
oblique section. We employed Image J (version 1.41) software to mea-
sure muscle ﬁbers within 4 muscle cross-sections from 4 different
mice belonging to each group. We then calculated themean and the re-
spective SEM.
2.11. mRNA extraction of muscle tissue
mRNA was extracted and puriﬁed using the Quiagen RNeasy mini
extraction kit (Hombrechtikon, Switzerland) with a DNA digestion
step to ensure RNA quality. RNA quality was evaluated with the
NanoDrop 2000 (Thermo Scientiﬁc, Wohlen, Switzerland). We then
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synthesized cDNA using the Quiagen omniscript system and used 10 ng
of cDNA for quantitative RT-PCR performed as described above.
2.12. Immunoblotting of muscle tissue
Expression of components of the AKT signaling pathway and of apo-
ptosis pathways was checked by Western Blotting. We homogenized
frozen muscle samples with a Micro-Dismembrator S (Sartorius,
Göttingen, Germany) during 1 min at 2000 rpm. We then resuspended
the tissue powder in protein extraction reagent (T-PER, thermo Scientif-
ic,Wohlen, Switzerland) containing a protease inhibitor cocktail (Roche
AG, Basel, Switzerland), centrifuged at 9000 g at 4 °C for 5min, collected
the supernatant and determined protein levels.
Protein separation, blotting and quantiﬁcation of the separated pro-
teins were performed as the in vitro samples described above.
2.13. TUNEL assay
TUNEL (terminal deoxynucleotidyltransferase-mediated dUTP nick-
end labeling) staining of myonuclei positive for DNA strand breaks
was performed using a commercially available ﬂuorescence detection
kit (Life Technologies, Zug, Switzerland). Cross sections (10 μm) ofmus-
cles cut with a cryostat microtome were ﬁxed with 4% paraformalde-
hyde for 15 min and the ﬁxed sections were permeabilized with
2mg/mL proteinase K. The TUNEL reaction mixture containing terminal
deoxynucleotidyltransferase (TdT) and ﬂuorescein-labeled dUTP was
added to the sections in portions of 50 μL and then incubated for
60 min at 37 °C in a humidiﬁed chamber in the dark. After incubation,
the sections were rinsed three times in PBS for 1 min each. Following
embedding with ProLong diamond antifade mountant with DAPI (Life
Technologies, Zug, Switzerland), the sections were investigated with a
ﬂuorescence microscope (Olympus BX61, Germany; 40× objective).
2.14. Statistical methods
Data are presented as mean ± SEM. Statistical signiﬁcance
(*P b 0.05; **P b 0.01, ***P b 0.001)was determined using one-way anal-
ysis of variance (ANOVA) followed by Dunnett's multiple comparison
test. We performed all the statistical analyses using GraphPad Prism 5
(GraphPad Software, La Jolla, CA, US).
3. Results
3.1. Statins are toxic for C2C12 myotubes
The cytotoxicity of simvastatin, rosuvastatin, and atorvastatin for
C2C12 myotubes was determined after exposure for 24 h by measuring
the release of adenylate kinase (AK) (Fig. 2). Treatment with 10 μM or
50 μM simvastatin or atorvastatin was associated with cell death at both
concentrations. In contrast, rosuvastatin was cytotoxic only at 50 μM.
3.2. Statins affect the AKT signaling pathway in C2C12 myotubes
We have shown previously that simvastatin impairs AKT activation
in C2C12 myotubes [14]. In order to answer the question whether this
effect is speciﬁc for simvastatin or can be observed also for other statins,
we investigated the effects of three different statins on components of
AKT signaling pathway. Because the activity of the proteins involved
in the AKT signaling pathway is mainly regulated by phosphorylation,
we examined the changes in the phosphorylation status of the key pro-
teins and related them to the expression level of the respective total
protein (see Fig. 1). As shown in Fig. 3A, simvastatin and atorvastatin
signiﬁcantly inhibited the phosphorylation of AKT at S473 (but not at
T308), of 4E-BP1 at S65 and of FoxO3a at S253 and T32 in a
concentration-dependent way. Simvastatin signiﬁcantly inhibited the
phosphorylation of rpS6 at S235/236, whereas atorvastatin showed
only a numerical, but not a statistically signiﬁcant inhibition. The high
concentration of rosuvastatin showed a signiﬁcant 60% reduction of
AKT phosphorylation at S473 as well as a signiﬁcant reduction of
FoxO3a phosphorylation at T32. Phosphorylation of S6K at T389 was
signiﬁcantly (P b 0.05) inhibited by simvastatin (53 and 87% at 10 and
50 μM, respectively), by simvastatin (8 and 15% at 10 and 50 μM, respec-
tively) and by 50 μMrosuvastatin (5%) (determined by ELISA and there-
fore not shown in Fig. 3).
Since the AKT-associated phosphorylation of FoxO3a prevents the in-
duction of muscle-speciﬁc atrophy genes such as the E3 ubiquitin ligases
atrogin-1/MAFbx andMuRF-1 [22],we investigated themRNAexpression
of atrogin-1/MAFbx and MuRF-1. As shown in Fig. 3B and C, atrogin-1/
MAFbx and MuRF-1 mRNA expression were increased concentration-
dependently in response to simvastatin and atorvastatin and, to lesser ex-
tent, also in response to rosuvastatin. These results suggest that statins, in
particular simvastatin and atorvastatin, may promote skeletal muscle
atrophy.
3.3. Statins have atrophic effects on C2C12 myotubes
It iswell established that activation of theAKT/mTOR signaling path-
way is implicated in skeletalmuscle hypertrophy in vitro and in vivo [21,
26,27]. To determine whether statins could induce an atrophic pheno-
type due to the inhibition of AKT, we examined responses of myotubes
to 10 μM and 50 μM simvastatin, atorvastatin or rosuvastatin. C2C12
myotubes were treated with the different statins for 24 h and assayed
for changes in myotube diameter. As shown in Fig. 4A and B, treatment
with simvastatin and atorvastatin resulted in a distinct atrophic pheno-
type, with a concentration-dependent decrease inmyotube diameter. In
contrast, rosuvastatin did not signiﬁcantly reduce the diameter of
myotubes. In agreement with myotube atrophy, simvastatin and ator-
vastatin were both associated with a signiﬁcant decrease in the total
protein content of the myotubes, whereas rosuvastatin decreased the
protein content only numerically without reaching statistical signiﬁ-
cance (Fig. 4C).
3.4. Statins induce apoptosis of myotubes
It is well established that inhibition of the AKT signaling pathway is
associated with apoptosis [17,28]. We therefore analyzed whether the
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inhibition of the AKT signalingpathway by statins is linkedwith apopto-
sis of C2C12 myotubes. Indeed, treatment of C2C12 myotubes with
10 μM or 50 μM simvastatin or atorvastatin for 24 h was associated
with increased expression of several markers of apoptosis, such as the
cleaved forms of caspase 9, caspase 3 and PARP (Fig. 5A). In contrast,
10 μM rosuvastatin was not associated with cleavage of the caspases
or of PARP, whereas 50 μM rosuvastatin caused a smaller increase in
markers of apoptosis than simvastatin or atorvastatin. In order to verify
that this increase in markers of apoptosis is associated with apoptosis,
we evaluated DNA fragmentation which is a feature of apoptotic cell
death. As expected, simvastatin and atorvastatin inducedDNA fragmen-
tation in a concentration-dependent fashion starting at 10 μM, while
rosuvastatin increased DNA fragmentation only at 50 μM (Fig. 5B).
3.5. Simvastatin impairs the AKT signaling pathway and induces apoptosis
in mice in vivo
To further conﬁrm the role of the AKT pathway in statin-
induced myotoxicity, we treated the mice orally with simvastatin
5mg/kg bodyweight/day for 21days.We then analyzed skeletalmuscle
proteins involved in the AKT pathway. Similar to the in vitro ﬁndings,
simvastatin signiﬁcantly inhibited the phosphorylation of AKT at S473
and FoxO3a at S253, resulting in up-regulation of mRNA of atrogin-1/
MAFbx, a gene involved in muscle atrophy (Fig. 6A and B). We then
analyzed whether the inhibition of the AKT signaling pathway by
simvastatin was linked to apoptosis in murine skeletal muscle. Indeed,
treatment with simvastatin for 21 days induced the cleavage of caspases
9 and 3, which are markers of apoptosis (Fig. 6C). In addition, TUNEL
positive myonuclei, representing DNA strand breaks and indicating
apoptosis, could only be detected in the gastrocnemius of mice treated
with simvastatin and not in controlmice (Fig. 6D). Theseﬁndings demon-
strated that the results obtained in vitro are reproducible in mice in vivo.
3.6. Simvastatin reduces the skeletal muscle ﬁber area in mice
To investigatewhether inhibition of AKTby simvastatin could induce
muscle atrophy also in vivo in mice, we examined the area of myoﬁbers
in mice treated with simvastatin for 21 days. Indeed, treatment with
simvastatin resulted in a signiﬁcant reduction of the myoﬁber area
(Fig. 7). The results show that simvastatin can induce muscle ﬁber atro-
phy not only in vitro, but also in mice in vivo.
4. Discussion
The current investigations were based on a previous study from our
laboratory in which we showed that simvastatin interferes with AKT
phosphorylation in C2C12 myotubes, but not in HepG2 cells [14]. The
results of the current study conﬁrmand expand theseﬁndings in several
ways. First, we could demonstrate that the inhibition of AKT phosphor-
ylation in C2C12myotubes is not speciﬁc for simvastatin, but can be ob-
served also for the other statins investigated, particularly for the
lipophilic atorvastatin. Second,we could demonstrate the consequences
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Fig. 3. Effect of statins on components of the AKT/mTOR pathway in C2C12 myotubes. C2C12 myotubes were cultured in serum-free medium for 24 h and then treated with 10 or 50 μM
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of impaired AKT phosphorylation both within the AKT signaling path-
way and for important cellular processes related to AKT signaling such
as skeletal muscle protein synthesis and breakdown as well as apopto-
sis. Third, we could show that these effects of statins are not only an
in vitro phenomenon, but can also be detected in mice treated with a
simvastatin dose which is comparable to the doses used in humans.
The fact that all statins investigated were cytotoxic and inhibited the
AKT signaling pathway (the more hydrophilic rosuvastatin to a lesser ex-
tent than the lipophilic simvastatin and atorvastatin) is compatible with
the assumption that the mechanism of AKT inhibition is associated with
themode of action of the statins, namely inhibition of cholesterol synthesis
at the level of hydroxymethylglutaryl-CoA (HMG)-CoA reductase. It has
been postulated that intermediates between HMG and cholesterol, in par-
ticular farnesyl-pyrophosphate and geranylgeranyl-pyrophosphate, which
are important for protein prenylation [12], can be diminished in skeletal
muscle of patients treated with statins to such an extent that myopathy
can occur [3]. This hypothesis is supported by the observation that the ad-
dition of mevalonate, but not of cholesterol, could at least partially pre-
vent myotoxicity associated with lovastatin in rabbits [29]. It is difﬁcult,
however, to explain by this mechanism why statins impair the AKT sig-
naling pathway. A possible explanation may be related to the observa-
tions that prenylation is important for the function of small GTPases
[12] and that statins can inhibit their prenylation [30]. Rab1, a prenylated
small GTPase, has been shown to stimulate AKT phosphorylation [31] and
to possibly be involved in statin-associated muscle damage [12,14]. Since
overexpression of Rab1 could not normalize AKT phosphorylation in
C2C12 myotubes exposed to simvastatin [14], the precise role of statin-
induced loss of Rab1 prenylation for impaired AKT activation is currently
not clear and needs further investigation.
A second possibility to explain the effect of statins on the AKT signal-
ing pathway is by the well-established mitochondrial toxicity of these
compounds [8,9,32,33]. By impairing the function of the mitochondrial
respiratory chain, statins decrease the skeletal muscle ATP and increase
the ADP content [34], leading to the activation of AMPK. AMPK activa-
tion is associated with impaired phosphorylation of AKT, as shown in
a recent study describing the toxicity of simvastatin cultured H9c2
cardiomyocytes and in mice in vivo [35].
Interestingly, all statins investigated impaired AKT phosphorylation
at S473, but not at T308 (Fig. 3A). AKT phosphorylation at S473 is per-
formedbymTORC2,whereasAKTphosphorylation at T308 is performed
by phosphoinositide-dependent kinase-1 (PDK1), a component of the
IgF-1 receptor/AKT pathway [36]. Taking into account that statins not
only impaired the activity of mTORC2, but also of mTORC1 (impaired
phosphorylation of S6K, rpS6 and 4E-BP1), a third possible mechanism
is impairment of mTOR, a component of both TORC1 and TORC2 [37]
by a so far not identiﬁed mechanism.
Independently of the mechanism leading to impaired AKT phos-
phorylation, the inhibition of the AKT signalingpathwayhad several im-
portant consequences on C2C12 cells and also on skeletal muscle of
mice treated with simvastatin. Statins that inhibited the phosphoryla-
tion of S6K, which impaired phosphorylation of the ribosomal protein
S6 (Fig. 3A) have an important role in mRNA translation and protein
synthesis [18]. Although we did not directly determine protein synthe-
sis by C2C12 myotubes in the current study, the observed reduction in
the protein content of C2C12 myotubes is compatible with impaired
protein synthesis, which is likely a consequence of impaired rpS6
phosphorylation.
In addition, AKT activation blocks protein degradation via the phos-
phorylation of FoxO3a, which impairs nuclear translocation of FoxO3a
and the subsequent expression of the muscle atrophy markers MuRF-1
and atrogin-1/MAFbx [22,26]. As expected in the case of impaired AKT
phosphorylation, we observed reduced phosphorylation of FoxO3a in
the presence of statins, which was associated with increased mRNA ex-
pression of MuRF-1 and atrogin-1/MAFbx (in mice treated with simva-
statin only the mRNA expression of atrogin-1/MAFbx was signiﬁcantly
increased). MuRF-1 and atrogin-1/MAFbx are associated with skeletal
muscle protein degradation, offering an additional explanation for the
observed decrease in the protein content of C2C12 myotubes and in
skeletal muscle atrophy observed in mice treated with simvastatin.
Statins are known to induce apoptosis in various cells types [8,9,35].
In our previous study in L6 cells (a rat skeletal muscle cell line) [8], we
postulated amitochondrial mechanisms for statin-associated apoptosis.
Similar ﬁndings were reported by Kwak et al. [9], who investigated the
effect of simvastatin in primary human myotubes. The current study
shows that statins can induce apoptosis in C2C12 myotubes and in
mice in vivo and indicates that statins can trigger apoptosis by inhibition
of theAKT signaling pathway. This interpretation is compatiblewith our
recent ﬁndings in cultured H9c2 cardiomyocytes [35] and with reports
about statin-induced apoptosis in cancer cells [38].
Interestingly, in the current study, we consistently observed a lower
toxicity of rosuvastatin compared to atorvastatin and simvastatin. In
agreement with this ﬁnding, in publications reporting skeletal muscle
adverse events for statins, it is generally agreed that lipophilic statins
such as simvastatin are more toxic than the more hydrophilic com-
pounds such as pravastatin [1,2,6]. Rosuvastatin, which is more hydro-
philic than simvastatin or atorvastatin, has a good safety record
regarding myotoxicity when used at the recommended dosage [39].
The results of the current study are in agreement with a previous
study from our laboratory showing that pravastatin was less toxic
than simvastatin and atorvastatin on cultured L6 cells and on isolated
rat skeletal muscle mitochondria [8]. Two possible explanations for
this ﬁnding are that hydrophilic statins have more difﬁculties to enter
cells than lipophilic compounds or that rosuvastatin is per se less toxic
for the AKT signaling pathway. The second possibility is less likely,
since rosuvastatin is the most potent statin currently on the market
and inhibition of HMG-CoA reductase is a likely toxicological mecha-
nism. Regarding the ﬁrst possibility, it is clearly established that differ-
ent organic anion transport proteins (OATP), which are responsible for
statin transport into the liver, are also expressed in skeletal muscle
[40] and are important for the transport of statins into skeletal muscle
[41]. At low concentrations, transport of both hydrophilic and lipophilic
statins into myocytes appears to be achieved mainly by OATPs [40]. At
the concentrations used in the current study, which may be reached in
the systemic circulation when transport of statins into the liver and/or
hepatic metabolism is blocked [41,42], diffusion may also play a role.
When diffusion becomes important, lipophilic statins may reach higher
intracellular concentrations than the hydrophilic compounds, possibly
explaining that simvastatin and atorvastatinweremore toxic in the cur-
rent studies than rosuvastatin.
Statin-associated rhabdomyolysis is a rare event, usually occurring
in patients treated with a therapeutic dose. Two well established risk
factors include a high systemic exposure [1] and underlying metabolic
muscle disease [43,44]. High systemic exposures in patients treated
with a therapeutic dose can result from inherited malfunction of the
transport mechanism into hepatocytes [7] or from drug-statin interac-
tions [42,45,46]. Regarding drug-statin interactions, mainly (but not ex-
clusively) the lipophilic statins are affected and the increase in the
systemic exposure can be substantial, leading to serum concentrations
in the low micromolar range [42]. The dependence of muscle toxicity
with statin exposure is clearly demonstrated also by the current studies
with C2C12 myotubes.
5. Conclusions
The current study demonstrates that statins are cytotoxic and impair
AKT phosphorylation in C2C12myotubes and in skeletal muscle of mice
in vivo. The lipophilic simvastatin and atorvastatin showed a higher
in vitro toxicity than the hydrophilic rosuvastatin. Impaired phosphory-
lation of AKT was associated with myoﬁbrillar atrophy and apoptotic
cell death of C2C12 myotubes. Similar ﬁndings were also obtained in
skeletal muscle of mice treated with simvastatin. These ﬁndings may
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have therapeutic implications, since activation of the AKT signaling
pathway may improve myopathy in patients treated with statins.
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1 Abstract		
Statins	 are	 drugs	 used	 to	 lower	 cholesterol	 levels.	 They	 are	 generally	 well-tolerated,	 but	 their	 use	 is	 frequently	 associated	 with	 dose-dependent	 skeletal	muscle	 damage.	 The	mechanisms	 by	which	 statins	 induce	myotoxicity	 are	 still	not	completely	understood.	Statins	have	been	shown	to	negatively	regulate	 the	AKT	signaling	cascade	with	an	unclear	mechanism,	whereas	insulin-like	growth	factor	 (IGF-1)	 is	 known	 to	 activate	 AKT	 signaling	 pathay	 and	 promote	muscle	growth.		The	 objective	 of	 the	 present	 study	 was	 to	 measure	 the	 effect	 of	 IGF-1	 on	simvastatin-induced	toxicity	in	C2C12	myotubes.	Myotubes	were	 exposed	 to	 10	 µM	 simvastatin	 and/	 or	 20	 ng/ml	 IGF-1	 for	 18	hours.	 Simvastatin	 inhibited	 IGF-1	 pathway	 blocking	 protein	 synthesis,	enhancing	 breakdown	of	myofibrillar	 proteins,	while	 also	 triggering	 apoptosis.	Conversely,	 simvastatin-induced	 myotoxicity	 was	 completely	 antagonized	 by	IGF-1.	Moreover,	the	protective	effect	of	IGF-1	was	mediated	by	the	activation	of	IGF-1/AKT	signaling	cascade	that	 led	to	a	suppression	of	atrophic	markers	and	apoptosis,	 and	 simultaneously	 triggered	 pro-synthetic	 pathways.	 These	 results	were	confirmed	by	the	maintenance	of	myotubes	morphology.		This	 study	provides	new insight	 into	 the	prevention	of	 statin	 toxicity	 and	may	herald new discoveries	 for	 the	 therapeutic	 intervention	 of	 the	 statin-induced	myalgia.		
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2. Introduction	
Statins,	 3-hydroxy-3-methylglutaryl	 coenzyme	 A	 reductase	 inhibitors,	 are		cholesterol	 lowering	 medications.	 They	 reduce	 morbity	 and	 mortality	 from	coronary	heart	disease	and	mitigate	the	risk	of	stroke	[1].		Statins	are	generally	well-tolerated,	however,	 they	can	also	produce	potentially	severe	adverse	reactions,	particularly	on	the	skeletal	muscle	[2].	Skeletal	muscle	injuries	 vary	 from	 mild	 myopathy	 to	 serious	 and	 clinically	 dangerous	rhabdomyolysis,	 a	 clinical	 condition	 characterized	 by	 the	 destruction	 of	 the	skeletal	muscle	fibers	and	release	of	their	contents	into	the	bloodstream	[3,	4].			Previous	 work	 from	 our	 group	 showed	 that	 simvastatin-induced	 myotoxicity	might	be	related	to	AKT	inhibition	[5].	AKT,	also	called	protein	kinase	B	(PKB),	is	a	major	effector	of	IGF-1	pathway	(Fig.1).	IGF-1/	AKT	pathway	plays	a	major	role	in	the	regulation	of	skeletal	muscle	growth.	IGF-1	is	considered	a	promising	anti-atrophic	 agent	 because	 of	 its	 ability	 to	 promote	 hypertrophy	 [6].	 It	 has	 been	demonstrated	that	administration	of	IGF-1	ameliorates	atrophic	settings	[7]	[8]	and	that	IGF-1	is	sufficient	to	induce	significant	skeletal	muscle	hypertrophy	via	the	 AKT	 signaling	 cascade	 in	 animal	 models	 [9,	 10	 ]	 and	 muscle	 cell	 culture	systems	[11,	12].	By	contrast,	skeletal	muscle	atrophy	has	been	associated	with	a	decreased	ability	to	activate	the	IGF-1/AKT	pathway	[13].		The	hypertrophic	effects	of	IGF-1	are	mediated	by	the	IGF-1	receptor	(IGF1R),	a	tyrosine	kinase	receptor	which	signals	through	the	AKT	pathway.	AKT	controls	both	protein	synthesis,	by	promoting	the	activation	of	the	mammalian	target	of	rapamycin	 (mTOR)	 and,	 protein	 degradation,	 by	 phosphorylating	 and	 thereby	suppressing	 the	 activation	 of	 forkhead	 members	 of	 the	 O	 class	 (FoxO)	transcription	factors	[14-16].	mTOR	 controls	 protein	 translation,	 through	 phosphorylation	 of	 the	 eukaryotic	translation	 initiation	 factor	 4E	 binding	 protein	 1	 (4E-BP1),	 and	 protein	transcription,	through	phosphorylation	of	the	ribosomal	protein	S6	kinase	(S6K)		[17-21].	AKT	 suppresses	 the	 nuclear	 translocation	 of	 the	 FoxOs	 transcription	 factors		[16].	FoxO	factors	are	required	for	the	transcriptional	regulation	of	two	ubiquitin	ligases	 in	 muscle:	 muscle	 atrophy	 F-box	 	 (MAFbx)	 also	 called	 atrogin-1	 and,	
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muscle	ring	finger	1	(MuRF-1).	These	E3	ubiquitin	ligases	conjugate	ubiquitin	to	muscle	proteins	(i.e.	myosin), targeting	them	for	degradation	by	the	ubiquitin–proteasome	 system. Growth	 factors	 or	 stress	 agents	 regulate	 FoxOs	 activation	through	 a	 shuttling	 mechanism	 [22].	 Growth	 factors	 stimulate	 the	phosphorylation	of	FoxO	proteins,	which	in	turn	provokes	the	nuclear	exclusion	and	 facilitates	 their	 degradation	 [19].	 Whereas,	 stress	 agents	 cause	 FoxOs	dephosphorylation,	 thereby	 accelerating	 their	 nuclear	 translocation	 and	subsequent	activation	[23-25]	[26].	Moreover,	 AKT	 is	 directly	 involved	 in	 regulating	 cell	 survival	 through	 the	suppression	 of	 apoptosis	 by	 phosphorylating	 and,	 therefore	 blocking,	 the	 pro-apoptotic	protein	BAD	and,	consequently	activating	the		caspase	cascade	[27].	In	this	work,	we	aimed	to	investigate	and	to	better	understand	the	role	of	IGF-1	in	the	prevention	of	simvastatin-induced	myotoxicity.		Since	we	have	previously	shown	that	simvastatin	triggers	apoptosis	and	atrophy	of	C2C12	myotubes	by	inactivating	AKT	pathway,	we	investigated	whether	IGF-1	could	 protect	 from	 simvastatin-induced	 atrophy.	 For	 this	 purpose,	 we	 first	studied	 the	 effects	 of	 simvastatin	 and	 IGF-1	 on	 C2C12	 myotubes	 cytotoxicity.	Further,	we	 characterized	 the	 effects	 of	 the	 combination	 of	 the	 two	 agents	 on	atrophic	and	apoptotic	markers.		This	study	increases	our	understanding	of	the	importance	that	IGF-1	has		on	the	statin-associated	muscle	atrophy	and	opens	the	door	to	a	future	development	of	specific	 modulators	 of	 IGF-1/	 AKT	 signaling	 cascade	 for	 the	 therapeutic	prevention	of	statin-induced	myotoxicity.			
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Fig.	 1.	 A	 simplified	 scheme	 of the	 IGF-1/AKT	 pathway	 and	 its	 main	
components.	Binding	of	IGF-1	to	its	receptor	leads	to	its	autophosphorylation	and	autoactivation.	 Subsequently,	 AKT	 translocates	 to	 the	 plasma	 membrane	 and	 is	phosphorylated	 on	 Ser	 473.	 Once	 activated,	 AKT	 inhibits	 protein	 degradation	 by	phosphorylating	 and	 thus	 repressing	 FoxOs	 transcription	 factors,	 and	 stimulates	protein	synthesis	via	the	mammalian	target	of	rapamycin	(mTOR).	Moreover,	AKT	also	blocks	apoptosis	inactivating	the	pro-apoptotic	protein	Bad.	
3. Materials	and	Methods	
3.1 	Chemicals	We	converted	simvastatin	into	the	active	acid	by	using	the	protocol	of	Bogman	et	al.	 [28].	 	Stock	solutions	were	prepared	 in	DMSO	and	stored	at	 -20°C.	All	other	chemicals	used	were	purchased	from	Sigma-Aldrich	(St.	Louis,	MO,	USA),	except	where	indicated.	
3.2 	Cell	lines	and	cell	culture	C2C12	 myoblasts	 were	 from	 the	 American	 Type	 Culture	 Collection	 kindly	provided	by	Novartis	(Basel,	Switzerland).	We	grew	cells	at	37°C	in	a	humidified	5%	CO2	cell	culture	incubator	and	we	passaged	them	using	trypsin.	Cell	number	
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was	determined	using	a	Neubauer	hemacytometer	and	viability	using	the	trypan	blue	exclusion	method.	We	initially	seeded	150,000	myoblasts	per	well	in	a	6-well	plate,	and	grew	them	for	 2	 days	 in	 growth	medium	 consisting	 of	Dulbecco’s	Modified	Eagle	Medium	(DMEM)	 +	 GlutaMAX,	 high	 glucose	 (4.5	 g/l)	 (Invitrogen,	 Basel,	 Switzerland)	containing	10%	heat-inactivated	fetal	bovine	serum	(Gibco,	Paisley,	UK).	Afterwards,	 we	 induced	 the	 differentiation	 using	 high	 glucose	 DMEM	(Invitrogen,	 Basel,	 Switzerland)	 supplemented	 with	 2%	 horse	 serum	 (Gibco,	Paisley,	UK),	 for	 3	 days.	 Then,	we	 incubated	 the	 cultures	 in	 serum-free	DMEM	(Invitrogen,	Basel,	Switzerland)	for	24	h	before	the	addition	of	the	compounds	to	test.	 Cell	 culture	 supplements	 were	 all	 purchased	 from	 GIBCO	 (Paisley,	 UK).		DMSO	was	used	as	a	control	and	its	concentration	was	always	0,1%.		After	18	h	treatment,	we	collected	cells	and	we	proceed	to	the	analysis	of	interest.		
3.3		Cytotoxicity		We	used	the	ToxiLight	BioAssay	Kit	(Lonza,	Basel,	Switzerland)	to	investigate	the	cytotoxicity	 of	 the	 compounds	 on	 C2C12	 myotubes.	 This	 assay	 measures	 the	release	of	adenylate	kinase,	a	marker	 for	 loss	of	 cell	membrane	 integrity.	After	drug	incubation,	we	added	100	μl	assay	buffer	to	20	μl	supernatant	from	drug-treated	cell	culture	medium,	and	we	measured	luminescence	after	incubation	in	the	 dark	 for	 5	min,	 using	 a	 Tecan	M200	 Pro	 Infinity	 plate	 reader	 (Männedorf,	Switzerland).	
3.4 	Cell	lysis		and	immunoblotting	After	drug	incubation,	we	homogenized	C2C12	myotubes	in	phosphosafe	buffer	(EMD	Millipore,	USA).	We	centrifuged	the	samples	at	1600	g	at	4°C	and	collected	the	 supernatant.	 We	 determined	 the	 whole	 protein	 content	 for	 each	 sample	using	BCA	Protein	Assay	Kit	(Pierce,	Thermo	Scientific,	Rockford,	U.S.A).	Lysates	were	 separated	 on	 4–12%	 Bis-Tris	 polyacrylamide	 gels	 (Invitrogen,	 Basel,	Switzerland)	 under	 reducing	 conditions	 and	 transferred	 to	polyvinylidendiﬂuoride	 membranes	 (EMD	 Millipore,	 Massachusetts,	 USA).	 We	blocked	 the	membranes	with	5%	nonfat	dry	milk	 in	DPBS	 (Gibco,	Paisley,	UK)	
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containing	 0.1%	 Tween-20	 (Sigma-Aldrich,	 MO,	 USA)	 for	 1	 h	 at	 room	temperature.	We	incubated	overnight	with	the	primary	antibody	(Cell	Signaling	Technology,	USA)	diluted	1:1000	in	blocking	buffer.	The	day	after,	we	incubated	the	blots	for	1	h	with	1:2000	of	secondary	antibody	(Santa	Cruz	Biotechnology,	USA)	 in	 5%	 nonfat	 milk	 in	 PBS-T,	 washed	 them	 and	 developed	 the	immunoreactive	bands	with	using	enhanced	chemiluminescence	(GE	Healthcare,	Buckinghamshire,	 United	 Kingdom).	 Chemiluminescent	 images	 were	 scanned	using	 an	 HP	 Scanjet	 8300	 (Hewlett-Packard	 Co.,	 Palo	 Alto,	 CA)	 and	 band	intensities	of	the	scanned	images	were	analyzed	using	the	National	Institutes	of	Health	 Image	 J	 program,	 version	 1.41.	 To	 correct	 loading	 differences,	 the	scanning	 units	 obtained	 from	 test	 proteins	 were	 divided	 by	 scanning	 units	obtained	from	the	housekeeping	protein	GAPDH.		
3.5 	Subcellular	fractionation	We	 used	 the	 NE-PER	 Nuclear	 and	 Cytoplasmic	 Extraction	 Reagents	 (Pierce,	Thermo	Scientific,	Rockford,	U.S.A)	to	separate	cytoplasmic	and	nuclear	protein	fractions.	 After	 drug	 incubation,	 we	 harvested	 C2C12	 myotubes	 with	 trypsin-EDTA	 and	 pelleted	 them	 by	 centrifuging	 at	 500	 ×	 g	 for	 5	 minutes.	 We	resuspended	the	pellet	with	ice-cold	CER	I	and	incubated	on	ice	for	10	minutes.	We	 added	 ice-cold	 CER	 II,	mixed	 and	 incubated	 on	 ice	 for	 1	minute.	 Then,	we	centrifuged	 the	 tube	 for	 5	 minutes	 at	 16,000	 g	 and	 we	 transferred	 the	supernatant	(cytoplasmic	extract)	to	a	clean	pre-chilled	tube.	In	order	to	isolate	the	nuclear	extract,	we	resuspended	the	pellet	in	ice-cold	NER,	vortexing	for	15	seconds	every	10	minutes,	 for	a	total	of	40	minutes.	At	the	end,	we	centrifuged	the	tube	at	16,000	g	for	10	minutes	and	we	transferred	the	supernatant	(nuclear	extract)	fraction	to	a	clean	pre-chilled	tube.		
3.6 	FoxO3a	translocation	assay	After	 fixing	 the	 cells	with	 4%	PFA,	we	permeabilized	 the	myotubes	with	 0,2%	Triton	in	PBS,	we	blocked	the	nonspecific	binding	with	10%	BSA	in	PBS	and	we	incubated	with	FoxO3a	antibody	(Cell	Signaling	Technology,	USA)	diluted	1:500	in	 PBS	 overnight.	 The	 day	 after,	 we	 washed	 the	 cells	 and	 we	 incubated	 with	
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Alexa	Fluor	594	F	 (AB’)	 (Invitrogen,	Basel,	Switzerland)	diluted	1:1000	 in	PBS.	We	then	stained	the	nuclei	with	DAPI	(Invitrogen,	Basel,	Switzerland).		The	distribution	of	FoxO3a	between	the	two	sub-cellular	compartments	nucleus	and	cytoplasm	was	analyze	and	measured	on	a	single	cell	level	in	C2C12-cells	by	use	of	the	Cytoplasm	to	Nucleus	Translocation	BioApplication	software	designed	for	 the	 ArrayScan	 HCS	 Reader	 (Cellomics	 Inc)	 as	 described	 earlier	 [29].	 The	average	 intensity	 of	 1000	 cells/well	 was	 quantified	 using	 a	 20X	 objective.	Cellular	focusing	and	definition	of	the	nuclear	region	was	performed	in	channel	1	(nuclear	 channel)	 according	 to	 the	 Hoechst-33342	 nuclear	 dye	 after	 a	 fixed	exposure	 time	of	80	ms,	FoxO3a	dependent	 fluorescence	was	visualized	within	channel	 2	 at	 488	 nm	 (300	ms).	Within	 the	 target	 channel	 2	 an	 algorithm	was	utilized	 to	 define	 two	 masks	 either	 corresponding	 to	 each	 nucleus,	 identified	within	channel	1,	or	the	cytoplasm	beyond	the	nuclear	region;	the	average	pixel	intensity	 within	 the	 separate	 masks	 of	 the	 target	 cannel	 were	 measured	 and	results	were	reported	as	mean	Nucleus-Cytoplasm	Intensity-Differences.	
3.7 	Real-Time	Polymerase	Chain	Reaction	(RT-PCR)	We	treated	C2C12	myotubes	with	the	drug	of	interest	for	18	h.	Afterwards,	RNAs	were	extracted	and	purified	using	the	Qiagen	RNeasy	mini	extraction	kit	(Qiagen,	Hombrechtikon,	 Switzerland).	 The	 purity	 and	 quantity	 of	 RNA	were	 evaluated	with	 the	 NanoDrop	 2000	 (Thermo	 Scientific,	 Wohlen,	 Switzerland)	 and	 cDNA	was	synthesized	from	10	μg	RNA	using	the	Qiagen	omniscript	system.		The	 real-time	 PCR	 was	 performed	 in	 triplicate	 using	 SYBR	 green	 (Roche	Diagnostics,	 Rotkreuz,	 Basel).	We	 used	 primers	 specific	 for	 the	 atrophic	 genes	MAFbx	 (forward:	 5'AGTGAGGACCGGCTACTGTG3',reverse:	5’GATCAAACGTTGCGAATCT3’and	 MuRF-1	 (forward:	5'CCTGCAGAGTGACCAAGGA3',	reverse:	5'GGCGTAGAGGGTGTCAAACT3').		Real	time	PCR	was	executed	by	using	the	ViiA7	software.	We	 calculated	 relative	 quantities	 of	 speciﬁcally	 ampliﬁed	 cDNA	 with	 the	comparitive-threshold	cycle	method.	GAPDH	was	used	as	endogenous reference	(forward:	 5′-CATGGCCTTCCGTGTTCCTA-3′;	 reverse:	5′CCTGCTTCACCACCTTCTTGA-3′).	 	 No-template	 and	 no-reverse-transcription	controls	ensured	that	unspeciﬁc	ampliﬁcation	could	be	excluded.	
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3.8 	Immunostaining	and	diameter	measurement	After	 fixing	 the	 cells	with	 4%	PFA,	we	permeabilized	 the	myotubes	with	 0,2%	Triton	in	PBS,	we	blocked	the	nonspecific	binding	with	10%	BSA	in	PBS	and	we	incubated	with	myosin	heavy	chain	(MHC)	(EMD	Millipore,	Massachusetts,	USA)	diluted	 1:1000	 in	 PBS	 overnight.	 The	 day	 after,	 we	 washed	 the	 cells	 and	 we	incubated	with	Alexa	Fluor	488	F	(AB’)	(Invitrogen,	Basel,	Switzerland)	diluted	in	 PBS.	We	 then	mounted	 cells	with	 ProLong	Gold	 antifade	 reagent	with	DAPI	(Invitrogen,	 Basel,	 Switzerland).	 To	measure	 diameters,	 we	 took	 four	 pictures	per	well	and	from	each	picture	we	measured	the	biggest	30	diameters	using	Cell	R	 software	 (Olympus	 Imaging	Australia	Pty	Ltd,	Tokyo,	 Japan).	Afterwards,	we	calculated	the	average	for	all	the	diameters	measured	in	each	well.		
3.9 	Apoptotic	DNA	fragmentation	assay	We	used	Apoptotic	DNA	Ladder	Kit	(Roche	Molecular	Biochemicals,	Mannheim,	Germany)	 to	 evaluate	 the	 Apoptotic	 DNA	 laddering	 under	 the	 conditions	described	by	the	manufacturer.	To	isolate	DNA,	cells	were	incubated	for	10	min	with	200	µL	of	lysis	buffer	(6	M	guanidine-HCl,	10	mM	urea,	10	mM	Tris-HCl,	and	20%	Triton	X-100,	pH	4.4).	Following	the	incubation	period,	we	added	100	µL	of	isopropanol	to	each	tube,	vortexed	the	samples,	added	them	to	filter	tubes,	and	centrifuged	for	1	min	at	5000	g.	Filter	tubes	were	washed	twice	with	500	µL	of	wash	buffer	 (20	mM	NaCl	and	2	mM	Tris-HCl,	pH	7.5).	Then,	200	µL	of	elution	buffer	 (10	mM	 Tris,	 pH	 8.5)	was	 added	 to	 each	 filter	 tube,	 and	 samples	were	centrifuged	at	6000	g	for	1	min.		DNA	content	and	integrity	were	determined	by	measuring	 samples	 absorbance	 at	 260	 nm	 using	 a	 NanoDrop	 2000	 (Thermo	Scientific,	Wohlen,	Switzerland).	We	used	1%	agarose	gel	in	TBE	buffer	(10	mM	Tris,	 80	mM	boric	 acid,	 1	mM	EDTA)	 containing	 ethidium	 bromide	 (Sigma)	 to	separate	and	visualize	DNA	bands.	DNA	was	added	at	5	µg/lane.	Gel	images	were	captured	using	a	Bio-Rad	Gel	Doc	2000	Imager	with	Quantity	One	software	(Bio-Rad	Laboratories).	
3.10		Protein	synthesis	assay	We	 determined	 the	 protein	 synthesis	 using	 the	 Click-iT®	 Plus	 OPP	 Protein	
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Synthesis	 Assay	 Kits	 (Invitrogen,	 Basel,	 Switzerland)	 following	manufacturers'	instructions.	 In	 brief,	 C2C12	 myotubes	 were	 treated	 for	 18	 h	 with	 the	compounds	 of	 interest.	 Afterwards,	 the	medium	 containing	 the	 treatment	was	removed	 and	 Click-iT®	OPP	was	 added	 into	 the	 well.	We	 incubated	 cells	 for	 1	hour.	Then	we	fixed	and	permeabilized	them	with	0.5%	Triton	X	100.	This	step	was	 followed	by	 incubation	 for	30	minutes	of	medium	containing	Click-iT®	OPP	reaction	 cocktail.	We	 remove	 the	 reaction	 cocktail	 and	 add	 the	 NuclearMask™	Blue	Stain	working	solution	incubating	for	30	minutes	at	room	temperature.		We	finally	wash	out	the	HCS	NuclearMask™	Blue	Stain	solution	and	we	proceeded	to	imaging	and	analysis.	
3.11		Statistical	Methods	All	the	data	were	analyzed	using	the	mean	+/-	standard	error	of	the	mean	(SEM)	and	statistical	significance	(*	P<	0.05;	**	P<	0.01,	***	P<	0.001)	was	determined	using	 one-way	 analysis	 of	 variance	 (ANOVA)	 followed	 by	 Dunnett’s	 multiple	comparison	test.	We	performed	all	the	statistical	analyses	using	GraphPad	Prism	5	(GraphPad	Software,	La	Jolla,	CA,	US).		
4. Results	
4.1 	IGF-1	 reduces	 the	 simvastatin-induced	 cytotoxic	 effects	 in	 a	 dose-dependent	
manner	Cytotoxicity	was	determined	by	measuring	adenilate	kinase	(AK)	release	(Fig.	2).	Incubation	 time	 and	 concentration	 were	 chosen	 based	 on	 results	 of	 previous	experiments	which	 showed	 that,	 the	 treatment	 of	 10	 µM	 simvastatin	 for	 18	 h	was	 the	 shortest	 incubation	 and	 the	 lowest	 concentration	 in	 which	 cell	 death	was	 significantly	 increased	 [5].	 AK	 release	 in	 C2C12	 myotubes	 treated	 with	simvastatin	 for	 18	 h	 was	 around	 1.7	 fold	 higher	 than	 that	 of	 control	 cells,	indicating	that	simvastatin	directly	affects	the	cell	membrane	integrity	and	has	a	cytotoxic	 effect.	 Interestingly,	 cells	 co-treated	 with	 simvastatin	 and	 increasing	concentration	 of	 IGF-1	 showed	 a	 dose	 dependent	 decrease	 in	 AK	 release	
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compared	 to	 simvastatin-	 treated	 cells.	 The	 total	 prevention	 by	 IGF-1	 was	observed	at	concentrations	ranging	from	10	ng/ml	to	100	ng/ml,	whereas,	lower	concentrations	prevented	simvastatin-induced	toxicity	only	to	a	lesser	extent.						 	 	 								 	 Cytotoxicity	assay	
	
Fig.	2.	IGF-1	counteracted	the	cytotoxic	effects	induced	by	simvastatin.	C2C12	myotubes	 were	 incubated	 with	 simvastatin	 and/or	 increasing	 concentration	 of	IGF-1	 for	 	 	 18	 h.	 Cell	 cytotoxicity	 was	 quantified	 using	 Toxilight	 assay	 and	expressed	as	ratios	to	the	DMSO	control.	O.1%	DMSO	and	triton	X	were	used	as	a	negative	and	positive	control	respectively.	Data	represent	the	mean	±	SEM	of	four	independent	experiments	carried	out	in	triplicates.		
4.2 	IGF-1R	inhibitor	blocks	the	IGF-1	preventive	effect	To	test	whether	the	IGF-1-mediated	prevention	depends	on	the	IGF-1	receptor,	we	performed	cell	cytotoxicity	assay	using	NVP-AEW541,	a	specific	 inhibitor	of	IGF-1	 receptor	 [30]	 [31].	We	 incubated	 rising	 concentrations	 of	 NVP-AEW541	for	 18	 h	 to	 define	 that	 10	 µM	 was	 the	 minimum	 concentration	 required	 for	effective	inhibition	of	the	IGF-1	receptor	(data	not	shown).		The	co-incubation	of	C2C12	myotubes	with	NVP-AEW541,	simvastatin,	and	IGF-1	for	 18	 h	 resulted	 in	 an	 increase	 in	 AK	 release	 of	 up	 to	 2.1	 fold	 above	 control	levels	and	up	to	1.1	fold	above	the	simvastatin	and	IGF-1	co-treatment.		To	further	evaluate	whether	the	increased	AK	release	did	not	actually	reflect	the	cytotoxicity	 of	 NVP-AEW541,	 we	 analyzed	 the	 cytotoxicity	 of	 the	 compound	alone.	The	 experiments	 revealed	 that	NVP-AEW541-treated	 cells	had	a	 slightly	increase	of	AK	release	of	up	to	1.4	above	control	levels	and	the	co-incubation	of	NVP-AEW541	together	with	IGF-1	(20	ng/ml)	did	not	abolish	this	effect.	Hence,	
Fig.&2&
DMSOTriton+XSMV+10µMIGF41+0.1+
ng/mlIGF41+1+ng
/ml
IGF41+10+n
g/ml
IGF41+100
+ng/ml
IGF41+0.1+
ng/ml++SM
V
IGF41+1+ng
/ml+++SMV
IGF41+10+n
g/ml+++SM
V
IGF41+100
+ng/ml+++S
MV0
1
2
3 Cytotoxicity+assay
AK+rele
ase
	 		
	 47	
IGF-1	receptor	triggers	the	prevention	of	simvastatin-induced	toxicity	and	IGF-1	pathway	 is	 crucial	 for	 the	 viability	 of	 the	 cells,	 indeed,	 if	 IGF-1	 receptor	 is	blocked,	 the	 cell	 viability	 decreases	 (Fig.	 3a).	 Moreover,	 we	 analyzed	 the	inactivation	of	 the	 receptor	by	western	blot	 just	 to	 confirm	our	hypothesis.	As	expected,	the	inhibitor	reduced	the	phosphorylation	of	the	receptor	under	basal	conditions	and	the	addition	of	IGF-1	could	not	restore	the	basal	phosphorylation	(Fig.	3b).	
4.3 	IGF-1	inhibits	the	protein	degradation	triggered	by	simvastatin	We	 previously	 showed	 that	 simvastatin	 blocks	 AKT	 activation	 [32].	 AKT	activation	 inhibits	 protein	 degradation	 by	 retaining	 forkhead	 transcription	factors	 (FoxOs)	 in	 the	 cytoplasm	 and,	 therefore,	 inhibiting	 the	 transcription	 of	several	 genes	 [26]	 [15].	 	 Here,	 we	 tested	 how	 the	 localization	 of	 FoxO3a	 is	regulated	 in	 the	 C2C12	 myotubes	 cotreated	 with	 simvastatin	 and	 IGF-1.	Subcellular	fractionation	and	western	blot	analysis	for	FOXO3a	were	performed.	Under	normal	condition	FOXO3a	was	predominantly	detected	in	the	cytoplasm.	By	contrast,	simvastatin	promoted	Foxo3a	nuclear	accumulation	and	this	effect	was	abolished	by	the	coincubation	with	IGF-1	(Fig.	4a).	These	results	were	also	confirmed	by	Foxo’s	traslocation	assay.	We	observed	a	nuclear	accumulation	of	FoxO3a	after	simvastatin	treatment	and,	a	sequestered	FoxO3a	in	the	cytoplasm	after	 the	 cotreatment	 IGF-1	 and	 simvastatin	 (Fig.	 4b).	 Collectively,	 these	 data	indicate	 that	 the	 shuttling	 and,	 therefore,	 the	 subsequent	 activation	 of	 FoxO3a	caused	by	simvastatin	are	prevented	by	IGF-1.	Furthermore,	to	understand	the	role	of	FoxO3a	in	simvastatin-treated	myotubes,	we	 investigated	 on	 the	mRNA	 expression	 of	 the	 ubiquitin	 ligase	 gene	MuRF-1	and	 MAFbx.	 These	 ubiquitin	 ligases	 are	 markers	 for	 muscle	 atrophy	 and	moreover,	 FoxO3a	 plays	 an	 important	 role	 in	 the	 transcriptional	 activation	 of	MuRF-1	and	MAFbx	[33,	34].	While	simvastatin	 induced	a	robust	expression	of	mRNAs	specific	for	MuRF-1	and	MAFbx,	the	co-treatment	with	IGF-1	prevented	completely	this	effect	(Fig.	5).	
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Fig.	 3.	 IGF-1	 receptor	 inhibitor	 (NVP-AEW541)	 blocked	 the	 IGF-1-mediated	
prevention	 accompanying	 cytotoxicity.	 (A)	 Inhibition	 of	 IGF-IR	 signaling-mediated	 by	 NVP-AEW541	 was	 determined	 in	 C2C12	 myotubes.	 Cells	 were	pretreated	with	10	μM	NVP-AEW541	for	2	h	and	then	stimulated	with	simvastatin	and/or	 IGF-1	 for	 18	 h.	 (A)	 Cell	 cytotoxicity	was	 quantified	 using	 Toxilight	 assay	and	 expressed	 as	 ratios	 to	 the	 DMSO	 control.	 (B)	 Representative	 blots	 of	 the	expression	of	phospho-	 IGF-1	receptor.	The	expression	of	 the	housekeeping	gene	GAPDH	was	analyzed	for	standardization.	Data	represent	the	mean	±	SEM	of	four	independent	experiments	carried	out	in	triplicates.	***P	<	0.001	vs.	DMSO	control.		
a					 	 	 	 	 b	
	
Fig.	4.	IGF-1	blocked	the	FoxO3a	activation	induced	by	simvastatin.	Cells	were	induced	with	 IGF-1	 and/or	 simvastatin	 for	 18	 h.	 0.1%	 DMSO	 and	 staurosporine	were	used	as	negative	and		positive	control	respectively.	(a)	Cells	were	lysed	and	subcellular	 fractionation	 was	 performed.	 FoxO3a	 was	 detected	 in	 the	 different	cellular	 subfractions.	 HSP90	 and	 HDAC	 were	 used	 as	 loading	 control	 for	 the	cytoplasmatic	fraction	and	for	the	nuclear	fraction	respectively.	Data	represent	the	mean	±	SEM	of	four	independent	experiments	carried	out	in	triplicates.	(b)	C2C12	myotubes	were	 stained	 using	 FoxO3a	 antibody.	 Nuclei	were	 stained	 using	 DAPI.	FoxO	 translocation	 after	 the	 treatment	 with	 the	 indicated	 compounds	 was	measured	 to	 evaluate	 Foxo’s	 activity.	 Data	 represent	 the	 mean	 ±	 SEM	 of	 four	independent	experiments	carried	out	in	triplicates.		
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Fig.	 5.	 IGF-1	 completely	 blocked	 simvastatin-upregulated	 MAFbx/MuRF-1	
expression	 in	 C2C12	 myotubes.	 Expression	 of	 the	 indicated	 ubiquitin	 ligase	genes	was	determined	by	real-time	PCR.		Data	represent	the	mean	±	SEM	of	three	independent	experiments	 carried	out	 in	 triplicates.	 	 *P	 <	0.05	and	**P	 <	0.01	 	vs.	DMSO	control.		
4.4 	IGF-1	blocks	the	myotubes	atrophy	induced	by	simvastatin	C2C12	myotubes	were	 treated,	 fixed	 and	 stained	with	 an	 antibody	 against	 the	myofibrillar	 protein	 myosin	 heavy	 chain	 (MHC).	 Immunofluorescence	 staining	revealed	that	exposure	to	10	µM	simvastatin	reduced	significantly	the	diameter	of	myotubes,	while	the	exposure	to	simvastatin	and	IGF-1	did	not	change	the	size	of	 the	myotubes.	This	 result	underscores	 that	 IGF-1	blocks	 the	development	of	the	muscle	atrophy	induced	by	simvastatin	(Fig.	6).	
4.5 IGF-1	prevents	apoptosis	in	simvastatin-treated	C2C12	myotubes		To	investigate	the	effect	of	IGF-1	on	simvastatin-induced	apoptosis,	we	evaluated	the	activity	of	key	mediators	in	the	apoptotic	signaling	cascade	such	as	the	pro-apoptotic	protein	BAD,	caspase	3	and,	PARP.	As	expected,	simvastatin	induced	a	dramatic	activation	of	the	apoptotic	markers	whereas,	the	co-incubation	of	IGF-1	and	 simvastatin	 inactivated	 pro-apoptotic	 proteins	 (Fig.	 7a).	 Moreover,	 we	analyzed	the	apoptotic	DNA	fragmentation,	one	of	the	hallmarks	of	apoptotic	cell	death.	 As	 shown	 in	 figure	 7b,	 simvastatin	 treatment	 induced	 apoptotic	 DNA	laddering	which	was	 totally	 prevented	 by	 the	 co-incubation	with	 IGF-1.	 These	data	suggest	that	IGF-1	is	able	to	abrogate	the	apoptosis	induced	by	simvastatin.				
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Fig.	 6.	 IGF-1	 blocked	 myotubes	 atrophy	 induced	 by	 simvastatin.	 C2C12	myotubes	 were	 treated	 with	 0,1%	 DMSO,	 20	 ng/ml	 IGF-1,	 and/or	 10	 μM	simvastatin	for	18	h.	(a)	Representative	immunostaining	using	MHC	antibody.	(b)	Myotube	 diameter	 after	 the	 treatment	 with	 the	 indicated	 compounds	 was	measured	 to	 evaluate	myotube	 atrophy.	 Data	 represent	 the	mean	 ±	 SEM	 of	 four	independent	experiments	carried	out	in	triplicates.		**P	<	0.01	vs.	DMSO	control.		
	
Fig.	 7.	 IGF-1	 abolished	 apoptosis	 induced	 by	 simvastatin	 treatment.	 C2C12	myotubes	 were	 treated	 with	 0.1%	 DMSO,	 20	 ng/ml	 IGF-1,	 and/or	 10	 μM	simvastatin	 for	 18	 h.	 Whole	 cell	 lysate	 were	 subjected	 to	 either	 Western	 blot	analysis	or	DNA	 laddering	assay.	(a)	Shown	are	representative	blots	of	apoptotic	markers.	 GAPDH	 levels	 are	 used	 as	 a	 loading	 control.	 Fold	 stimulation	 of	 the	apoptotic	 proteins	 was	 quantitated	 with	 Image	 J	 (numbers	 below	 bands).	 (b)	Ladder-like	pattern	of	DNA	fragmentation	into	oligonucleosome-length	fragments	was	 observed	 after	 simvastatin	 treatment	 suggesting	 an	 apoptotic	 event.	 Results	are	representative	of	three	independent	experiments.		
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4.6 	IGF-1	restores	the	protein	synthesis	blocked	by	simvastatin	To	further	understand	the	molecular	mechanisms	contributing	to	the	protective	effect	 of	 IGF-1	 on	 simvastatin-treated	 C2C12	 myotubes,	 we	 examined	 the	expression	of	AKT	downstream	effectors	involved	in	protein	synthesis.		As	shown	in	figure	8,	IGF-1	remarkably	abolished	the	specific	inhibition	of	AKT	pathway	 induced	by	simvastatin	restoring	 the	 levels	of	expression	of	phospho-AKT,	phospho-S6K	and	phospho-4EBP1.		Next,	we	 examined	whether	 the	myoprotective	 effect	 of	 IGF-1	 observed	 in	 our	C2C12	model	could	be	attributed,	at	least	in	part,	to	a	restoration	of	the	protein	synthesis.	Using	a	fluorescent	labeled	methionine,	we	were	able	to	visualize	the	overall	 protein	 synthesis	 after	 the	 treatment	 with	 the	 drug	 of	 interest.	Simvastatin-treated	 myotubes	 appeared	 to	 have	 a	 decrease	 in	 methionine	content	 compared	 to	 control	 cells.	 By	 contrary,	 the	 cotreatment	 IGF-1	 and	simvastatin	showed	a	complete	restoration	of	the	protein	synthesis	(Fig.	9a).	In	addition,	to	confirm	these	results,	we	measured	the	total	protein	content	isolated	from	 C2C12	myotubes	 after	 treatments.	 As	 expected,	 simvastatin-treated	 cells	showed	a	significant	decrease	in	the	overall	protein	content	which	is	not	seen	in	the	co-treated	cells	(Fig.	9b).	Taken	together,	these	findings	indicate	that	IGF-1	is	able	 to	 reactivate	 the	 protein	 synthesis	 blocked	 by	 simvastatin	 through	 the	activation	 of	 the	 AKT	 pathway,	 and	 the	 protein	 synthesis	 plays	 a	 role	 in	 the	prevention	of	statin–	induced	toxicity.			
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Fig.	 8.	 The	 protective	 effects	 of	 IGF-1	 are	 correlated	 with	 an	 efficient	
restoration	 of	 the	 AKT	 pathway.	 C2C12	 myotubes	 were	 treated	 with	 the	indicated	compounds	 for	18	h.	Whole	cell	 lysates	were	subjected	 to	western	blot	analysis.	Representative	blots	of	basal	expression	levels	of	phospho-	AKT	Ser	473,	phospho-rpS6	 Ser	 235/236	 and	 phospho-4E-BP1	 Ser	 65.	 The	 relative	 levels	 of	indicated	 proteins	 were	 quantitated	 with	 Image	 J	 and	 normalized	 to	 the	 total	protein	 (numbers	 below	bands).	 GAPDH	was	 used	 as	 a	 loading	 control.	 Data	 are	representative	of	four	independent	experiments.		
	
Fig.	 9.	 IGF-1	 restored	 the	 protein	 synthesis	 blocked	 by	 simvastatin.	 C2C12	myotubes	were	treated	with	the	indicated	compounds	for	18	h.		(a)	Representative	immunohistochemical	staining	of	methionine	in	C2C12	myotubes.	(b)	Total	protein	content	 isolated	 from	 C2C12	 myotubes	 after	 treatment	 with	 the	 indicated	compounds.	 Data	 represent	 the	 mean	 ±	 SEM	 of	 four	 independent	 experiments	carried	out	in	triplicates.		***P	<	0.001	vs.	DMSO	control.	
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5. Discussion	
The	 present	 study	 demonstrates	 for	 the	 first	 time	 that	 IGF-1	 acts	 as	 a	master	regulator	in	simvastatin-induce	myotoxicity	by	coordinating	simultaneously	the	activation	 of	 protein	 synthesis	 and,	 the	 repression	 of	 protein	 degradation	 and	apoptosis. 	Previous	study	reported	that	statins	interfere	with	AKT	phosphorylation,	which	might	be	related	to	the	toxicity	of	statin	in	skeletal	muscle	[32,	35].	In	addition,	statins	have	been	demonstrated	to	induce	apoptosis	in	various	type	of	cells	[36,	37],	 whereas	 IGF-1	 pathway	 is	 an	 essential	 anti-apoptotic	 molecular	 pathway	that	 confers	 the	 survival	 to	 cells	 [38]	 [39]	 and	 stimulates	 muscle	 growth	 by	inhibiting	 the	protein	degradation	 [6].	 	 Recent	 studies	 showed	 that	 IGF-1/AKT	pathway	 could	 dominantly	 reverse	 the	 atrophy-inducing	 effects	 of	dexamethasone	[40]	[26];	whereas	no	data	exist	concerning	the	direct	impact	of	IGF-1	on	statin	treated	muscle	cells.	We	 therefore	 explored	 the	 possibility	 whether	 IGF-1	 could	 also	 reverse	 the	myotoxic	 effects	 induced	 by	 simvastatin	 in	 C2C12	 myotubes.	 We	 incubated	myotubes	with	10	µM	simvastatin	and/or	increasing	concentrations	of	IGF-1	for	18	h.	The	co-incubation	with	simvastatin	and	IGF-1	revealed	a	dominantly	dose-dependent	 reduction	 in	 statin-induced	 cytotoxicity.	 It	 is	 worth	 to	 notice	 that	simvastatin	 concentration	 exceeds	 the	 peak	 reached	 in	 the	 plasma	 of	 patients	which	 is	 about	 1	µM	 [41].	 However,	 localized	 concentration	 in	 skeletal	muscle	could	 be	 higher,	 especially	 if	 statins	 are	 combined	 with	 cytochrome	 P450	inhibitors	or	with	transporters'	dysfunction	[42].	Further,	 to	 confirm	 the	 key	 role	 of	 the	 IGF-1/AKT	 pathway	 in	 blocking	 statin-	induced	 cytotoxicity,	 we	 exploited	 a	 pharmacological	 approach.	 We	 used	 a	specific	 inhibitor	 of	 IGF-1	R	 [30	 ],	NVP-AEW541,	 and	we	 analyze	 the	 cytotoxic	profile.	 The	 co-incubation	 of	 C2C12	myotubes	with	NVP-AEW541,	 simvastatin,	and	IGF-1	for	18	hours	resulted	in	an	increase	in	AK	release,	blocking	completely	the	 survival	 signals	 triggered	by	 IGF-1.	Hence,	 IGF-1	 induces	 the	prevention	of	simvastatin-induced	toxicity	through	the	activation	of	its	receptor.		Moreover,	since	IGF-1	has	been	shown	to	repress	protein	degradation	retaining	FoxO3a	 in	 the	 cytoplasm	 [43],	 we	 analysed	 the	 FoxO3a	 translocation	 into	 the	
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nucleus	and	the	subsequent	 induction	of	atrophic	markers	MuRF-1	and	MAFbx	after	the	treatment	with	IGF-1	and/or	simvastatin.		In	this	study	we	showed	that	IGF-1	 through	activation	of	AKT	retains	FoxO3a	 in	 the	cytoplasm	and	prevents	the	upregulation	of	MuRF-1	and	MAFbx	induced	by	simvastatin.	The	inactivation	of	this	proteolytic	pathway	by	IGF-1	indicates	that	the	prevention	of	simvastatin-associated	muscle	atrophy	results	not	only	from	a	suppression	in	cell	death,	but	also	from	a	maintenance	of	myofibrillar	proteins.	Indeed,	using	C2C12	myotubes,	we	showed	that	simvastatin	directly	stimulates	muscle	catabolism	affecting	the	myotube	 morphology,	 and	 interestingly,	 this	 catabolic	 effect	 is	 completely	blocked	by	IGF-1.		In	addition,	since	several	works	implicate	IGF-1	in	blocking	apoptosis	in	various	cell	 types	 [44]	 [45]	 [46]	 and,	 IGF-1	 is	 known	 to	 exert	 anti-apoptotic	 effects	blocking	 the	 activation	 of	 caspases	 [27],	 we	 explored	 the	 possibility	 that	 the	protective	 effect	 of	 IGF-1	 on	 simvastatin-induced	 cytotoxicity,	 might	 be	 also	related	 to	an	 inhibition	of	apoptosis.	Our	data	confirmed	our	hypothesis.	 IGF-1	negatively	 regulated	 apoptotic	 markers	 such	 as	 BAD,	 caspase	 3	 and	 cleaved	PARP	 leading	 to	 a	 complete	 inhibition	of	 apoptosis.	 Indeed,	 the	 apoptotic	DNA	laddering	assay	confirmed	that	IGF-1	completely	prevents	the	apoptosis	induced	by	simvastatin.	These	findings	are	consistent	with	previous	work	that	reported	that	 IGF-1/AKT	 signaling	 interferes	 with	 drug-induced	 apoptosis	 [47]	 and	pointed	 out	 that	 the	 anti-apoptotic	 and	 anti-atrophy	 signals	 of	 IGF-1	 interfere	with	the	toxicity	of	simvastatin.	IGF-1	 is	 a	 potent	 anabolic	 factor	 and	 animals	 treated	 with	 IGF-1	 reported	 a	generalized	increase	in	protein	synthesis	[48].	Activation	of	IGF-1	receptor	by	its	ligand	 initiates	 intracellular	 signaling	 cascade	 that	 results	 in	 the	 stimulation	of	AKT	signaling	pathway [40,	49].	In	skeletal	muscle,	IGF-1	directly	stimulates	AKT	inducing	 a	 phosphorylation	 cascade	 that	 leads	 to	 an	 inhibition	 of	 protein	breakdown	but	also	 to	stimulation	of	 the	protein	synthesis	 [50].	Therefore,	we	extended	 our	 investigation	 focussing	 on	 two	 downstream	 effectors	 of	 mTOR	involved	 in	 protein	 synthesis:	 S6K	 and	 4E-BP1.	 These	 proteins,	 once	phosphorylated	 by	 mTOR,	 upregulate	 the	 protein	 translation	 maschinery	 and	promote	 the	 protein	 translation	 [51]	 [52].	 Our	 data	 demonstrate	 that	 the	AKT/mTOR/S6K	pathway	impacted	by	simvastatin	can	be	completely	rescued	by	
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the	addition	of	IGF-1.		We	finally	then	shed	light	on	the	role	of	the	AKT/mTOR/S6K	pathway	in	the	IGF-1-induced	 prevention	 of	 muscle	 wasting	 associated	 with	 simvastatin,	 by	exploring	the	protein	synthesis	and	the	overall	protein	content.	Immunostaining	pictures	 showed	 that	 the	 expression	 of	 methionine	 was	 markedly	 reduced	 in	simvastatin-treated	myotubes	and	completely	restored	in	myotubes	treated	with	IGF-1	 and	 simvastatin.	 These	 results	 were	 further	 confirmed	 by	 the	measurement	 of	 total	 protein	 in	 C2C12	 myotubes	 after	 treatment	 with	 IGF-1	and/or	 simvastatin.	 Simvastatin	 induced	 a	 significant	 decrease	 of	 the	 whole	protein	content	which	is	completely	prevented	by	the	addition	of	IGF-1.	While	 previous	 studies	 have	 shown	 that	 IGF-1	 elicits	muscle	 hypertrophy	 [48]	[53]	[54]	and	inhibits	[55]	or	ameliorates	muscle	atrophy	[56],	we	demonstrate	for	 the	 first	 time	 that	 IGF-1	 can	 counteract	 the	 atrophy	 stimuli	 induced	 by	simvastatin	 by	 suppressing	 catabolic	 pathways	 associated	 with	 MAFbx	 and	MuRF-1	and	triggering	anabolic	signaling	associated	with	S6K	and	4EBP1.		In	addition,	IGF-1	and	insulin	downstream	signalling	are	largely	overlapping. Our 
data may also	partially	explain	reported	risk	of	statins	in	inducing	type	2	diabetes	[57].	Indeed,	statin	treatment	may	result	in	a	truncated	insulin	response	caused	by	the	impairment	of	AKT	phosphorylation.	Diabetic	setting	due	to	an	impaired	activation	 of	 AKT	 in	 response	 to	 insulin	 has	 been	 then	 described	 in	 several	independent	studies		[58]	[59]	[60].	In	summary,	our	study	provides	first	evidence	that	the	IGF-1	blocks	simvastatin-induced	 myotoxicity	 by	 potently	 restoring	 the	 IGF-1/AKT	 signaling	 pathway	suppressed	by	simvastatin.		Hence,	 inducing	IGF-1R	may	be	a	promising	approach	to	overcome	the	skeletal	muscle	 toxicity	 caused	 by	 statins.	 Therefore,	 our	 in	 vitro	 data	 merit	 a	confirmation	 in	vivo	 to	 test	 the	clinical	effects	of	a	compound	IGF-1-like	 for	 the	treatment	of	myalgia	associated	with	statins.		
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Conclusions	and	future	perspectives	
Since	their	introduction	in	the	1980s,	statins	have	emerged	as	first-choice	drugs	for	 lowering	 serum	 cholesterol	 level	 [36].	 Because	 of	 their	 pharmacological	activity,	they	are	the	best	selling	prescription	drugs	in	the	Western	Countries	[1].		Although	statins	have	a	favorable	safety	profile,	adverse	drug	reactions	can	occur	[1].	 The	 most	 relevant	 and	 well-documented	 side	 effect	 is	 myotoxicity,	 which	ranges	 from	 mild	 myopathy	 to	 a	 potentially	 fatal	 rhabdomyolysis	 [37,	 89].	Muscle	 toxicity	 associated	 with	 statins	 is	 dose-dependent,	 and	 the	 risk	 is	amplified	 by	 drug	 interactions	 that	 increase	 statin’s	 plasma	 levels	 and	bioavailability	[90,	91]	[92].	Adverse	events	can	occur	with	the	use	of	any	statin	but	the	degree	of	risk	within	the	therapeutic	dose	range	varies	among	statins	[2].	Despite	the	fact	that	statins	are	 proven	 to	 be	 well-tolerated	 medications,	 currently	 there	 are	 millions	 of	patients	worldwide	taking	statins	everyday	thus	reaching	a	significant	number	of	people	who	 present	 side	 effects	 [4].	Moreover	 they	 are	 chronic,	 generally	 life-long,	 lipid-lowering	 therapy	meaning	 side	 effects,	 even	 though	 rare,	 adversely	impact	on	the	patient's	quality	of	life	and	lead	to	noncompliance	[11].	Due	to	all	these	reasons,	there	is	an	urgent	need	to	discover	precise	mechanisms	of	statin-associated	myotoxicity.		
AKT/mTOR	signaling	pathway	plays	a	key	role	in	statin-
induced	myotoxicity	
The	 primary	 objective	 of	 this	 study	 was	 to	 investigate	 on	 the	 molecular	mechanisms	 of	 statin-induce	 toxicity	 in	 skeletal	 muscle.	 For	 this	 purpose,	 we	used	the	well-	characterized	murine	skeletal	muscle	model,	 the	cell	 line	C2C12,	optimized	 for	myotube	 formation.	Previous	 study	 from	our	group	 showed	 that	AKT	 is	negatively	 regulated	by	 simvastatin	 treatment	 in	C2C12	myotubes	 [56].	Taking	into	consideration	this	previous	finding,	we	examined	the	ability	of	three	
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structurally	distinct	statins	to	affect	the	AKT/mTOR	signaling	pathway	with	the	aim	 of	 uncovering	 differences	 between	 them	 that	 might	 point	 out	 to	 their	mechanism	of	 toxicity	 in	skeletal	muscle.	We	chose	 three	statins	with	different	pharmacological	 and	 toxicological	 profiles:	 simvastatin,	 rosuvastatin	 and	atorvastatin.	Simvastatin	and	atorvastatin	are	both	lipophilic	drugs	with	a	higher	incidence	for	myopathies	compared	to	maximum	approved	doses	of	other	statins	available	 on	 the	 market	 [22,	 93].	 Whereas,	 rosuvastatin	 is	 a	 relatively	hydrophilic	drug	with	a	safer	pharmacological	profile	than	other	statins	[14,	94].	The	 comparison	of	 the	 three	 statins	 revealed	 that	myotubes	were	 significantly	more	susceptible	to	simvastatin	and	atorvastatin	than	to	rosuvastatin. 	We	supposed	that	lipophilic	statins,	such	as	simvastatin	and	atorvastatin,	induce	higher	 cytotoxic	 effects	 in	 skeletal	 muscle	 cells	 because	 of	 their	 physical-chemical	 properties	 [95].	 Their	 lipophilic	 structure	 allows	 them	 to	 easily	penetrate	 cell	 lipid	 bilayer	 membrane	 barriers [24]	 while	 hydrophilic	 statins,	such	as	rosuvastatin,	are	membrane-impermeable	and,	therefore,	they	rely	on	an	active	transport	process	to	enter	cells	and	exert	their	effects	[6].		When	 comparing	 the	 effect	 of	 these	 three	 different	 statins	 on	 AKT	 signaling	pathway,	we	observed	an	inhibition	of	AKT	and	its	downstream	effectors	in	both	simvastatin-	and	atorvastatin-treated	C2C12	myotubes.	In	contrast,	rosuvastatin	exhibited	 a	 much	 weaker	 inhibition	 of	 AKT	 signaling	 cascade.	 These	 data	 are	completely	 in	 line	with	 the	 cytotoxicity	 data	 of	 these	 statins,	 and	highlight	 the	key	role	of	AKT	signaling	pathway	in	cell	survival		[96]	[97]	[98].	Because	 of	 the	 importance	 of	 AKT	 in	 regulating	 several	 processes	 such	 as	apoptosis,	protein	synthesis,	protein	breakdown,	we	investigated	on	the	effect	of	the	suppression	of	AKT	pathway.	We	could	confirm	that	the	cytotoxicity	is	due	to	AKT	 inhibition	 that	 in	 turn,	 led	 to	 induction	 of	 atrophy	 and	 apoptosis.	 Indeed,	simvastatin-	 and	 atorvastatin-treated	 C2C12	 myotubes	 showed	 a	 reduction	 in	whole	protein	content,	a	perturbation	of	 	myotubes	morphology	 	and	induction	of	 apopoptosis,	 whereas	 rosuvastatin-treated	 myotubes	 were	 affected	 only	 at	high	concentration	and	to	a	lesser	extent	than	the	other	two	statins.		In	conclusion,	this	part	of	the	thesis	fully	characterized	the	distinct	responses	to	lipophilic	 and	 hydrophilic	 statins	 in	 C2C12	 myotubes,	 identifing	 a	 key	 role	 of	AKT/mTOR	signaling	pathway	in	statin-associated	muscle	toxicity.		
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Lipophilic	 statins	 cross	 the	 cell	 membrane	 of	 C2C12	 myotubes	 by	 passive	diffusion.	 Once	 inside	 the	 cells,	 they	 inhibit	 AKT/mTOR	 signaling	 pathway	leading	 to	 activation	 of	 the	 atrophy	 pathways	 and	 promotion	 of	 the	 apoptotic	cascade.	 All	 these	 effects	 stimulate	 muscle	 wasting.	 By	 contrary,	 hydrophilic	statins	 have	 more	 difficulty	 to	 permeate	 inside	 muscle	 cells,	 and	 therefore	 to	exert	 the	 inhibition	 of	 AKT/mTOR	 pathway	 associated	 with	 the	 consequent	myotoxic	effects.		Recently	 discovered	 pleiotropic	 effects	 [38]	 [12]	 and	 uses	 [99]	 [13]	 of	 statins	attracted	 increasing	 interest	 in	 the	 scientific	 community.	However,	 an	effective	treatment	 that	 counteracts	 muscle	 damage	 linked	 to	 statin	 use	 is	 not	 yet	clinically	available	[3,	8].	Although	further	works	are	needed	to	understand	how	lipophilic	 statins	 efficiently	 block	 AKT/mTOR	 signaling	 pathway,	 this	 new	understanding	 suggests	 several	 potentially	 therapeutic	 targets,	 such	 as	inhibitors	of	FoxOs	or	activators	of	S6K,	to	prevent	statin-associated	myotoxicity.		Even	though	our	findings	provide	critical	insight	into	the	molecular	mechanisms	of	statin-induced	myotoxicity,	our	in	vitro	data	should	be	corroborated	by	in	vivo	studies	 in	transgenic	and	knockout	animal	models	 involving	components	of	the	AKT/mTOR	pathway	 to	confirm	our	hypothesis	and	 to	 identify	a	key	 factor	 for	preventing	 statin-induced	 myotoxicity.	 Nevertheless,	 it	 is	 noteworthy	 that	differences	between	in	vitro	and	in	vivo	models	and,	clinical	protocols	might	lead	to	 different	 conclusions.	 For	 instance	 proteasome	 inhibitors,	 which	 have	 been	successfully	used	to	antagonize	atrophy	 in	different	animal	models	 [100]	[101]	in	patients	displayed	cardiac	complications	[102].		Moreover,	since	AKT	is	at	 the	 intersection	of	different	pathways,	 it	plays	major	roles	in	several	biological	processes	[78,	103]	and,	it	has	been	also	implicated	in	the	molecular	 pathogenesis	 of	 several	 tumors	 [104]	 [105]	 [106].	 Due	 to	 these	reasons,	 it	 might	 be	 arduous	 to	 overcome	 these	 malign	 effects	 with	pharmacologic	manipulation.		Nonetheless,	this	study	reveales	a	central	role	of	AKT	signaling	cascade	in	muscle	damage	 associated	with	 statins	 and	 provides	 promising	 targets	 for	 developing	novel	therapeutic	approaches.		
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IGF-1	prevents	simvastatin-induced	myotoxicity	
In	 our	 previous	 work,	 we	 showed	 that	 AKT/mTOR	 signaling	 pathway	 has	 a	crucial	 role	 in	 regulating	 muscle	 atrophy	 associated	 with	 statins.	 Moreover,	simvastatin	showed	pronounced	toxic	effects	on	C2C12	myotubes.	Therefore,	in	our	 second	 study,	 we	 investigated	 whether	 an	 AKT	 inducer	 could	 reduce	myotoxicity	associated	with	simvastatin.		IGF-1	is	well	known	for	its	hypertrophic	and	anti-apoptotic	effect	[9]	exerted	by	activating	 IGF-1/AKT	 pathway	 [10].	Moreover,	 recent	 studies	 showed	 that	 the	IGF-1/AKT	 pathway	 could	 dominantly	 antagonize	 the	 atrophy	 induced	 by	dexamethasone	[9]	 [80];	whereas	no	data	exist	concerning	the	direct	 impact	of	IGF-1	 on	 muscle	 atrophy	 associated	 with	 statins.	 Combining	 these	 previous	findings,	we	 assumed	 that	 IGF-1	might	 antagonize	 the	myotoxicity	 induced	 by	statins.	 This	 idea	 was	 further	 confirmed	 by	 our	 results	 showing	 that	 the	simvastatin-induced	 cytotoxicity	was	 significantly	decreased	by	 the	addition	of	IGF-1.	The	prevention	of	cytotoxicity	was	strictly	correlated	by	the	activation	of	IGF-1R	and	its	downstream	signalling	pathway.	We	demonstrated	that	activation	of	 IGF-1	receptor	by	IGF-1	results	 in	the	reactivation	of	AKT	signaling	pathway	inhibited	 by	 simvastatin.	 This	 reactivation	 impairs	 statin-induced	 muscle	atrophy	 by	 stimulating	 both	 activation	 of	 protein	 synthesis	 and	 impairment	 of	protein	degradation	and	apoptosis.	Our	 data	 are	 in	 agreement	 with	 previous	 findings,	 showing	 that	 IGF-1/AKT	pathway	 is	 essential	 for	 cell	 health,	 and	 decrease	 in	 AKT	 phosphorylation	 is	correlated	with	increased	muscular	atrophic	signals	and	displayed	an	increase	in	apoptosis	[107,	108].	Moreover,	 it	 is	 noteworthy	 to	 mention	 that	 our data may partially	 explain	reported	risk	of	statins	in	inducing	type	2	diabetes	[111]	[112].	IGF-1	and	insulin	share	downstream	signalling	components,	 such	as	AKT	 [109].	Therefore,	 statin	treatment	may	result	in	a	truncated	insulin	response	caused	by	the	impairment	of	AKT	phosphorylation	[110].		In	 conclusion,	 IGF-1	 reduces	 statin-induced	 cytotoxicity	 in	 a	 dose-dependent	manner	via	reactivating	IGF-1/	AKT	signaling	pathway	and	thus,	exerting	strong	
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anti-apoptotic,	anti-	atrophy	and	hypertrophic	effects.		The	 data	 presented	 herein	 highlights	 that	 IGF-1	 has	 a	 strong	 potential	 for	 the	prevention	 or	 treatment	 of	 muscle	 atrophy	 associated	 with	 statins.	 Moreover,	the	 IGF-1/AKT	 signaling	 cascade	 is	 unique	 since	 it	 controls	 both	 protein	synthesis	 and	 protein	 degradation.	 Therefore,	 IGF-1	 mimetics	 might	 be	extremely	useful	for	counteracting	muscle	atrophy	and	weakness.		Nevertheless,	 IGF-1	 regulates	 many	 biological	 processes	 and	 its	 prolonged	activation	 might	 be	 detrimental	 for	 muscle	 cells.	 Moreover,	 the	 diabetogenic	effects	 [113]	 and	 the	 cancer	 risk	 associated	with	 IGF-1	 treatment	 [114]	 [115]	might	 be	 difficult	 to	 overcome	with	 pharmacological/	 chemical	manipulations.	The	 development	 of	 a	 new	 generation	 of	 IGF-1	 analogs	 that	 specifically	 target	part	of	 the	AKT	pathway	 in	skeletal	muscle	 is	a	goal	 for	 the	 field. For	 instance,		ubiquitin	 ligases	 involved	 in	 degradation	 of	 sarcomeric	 proteins	 should	 be	pursued.	However,	 it	should	be	considered	that	prolonged	inhibition	of	protein	degradation	 can	 have	 deterious	 conseguences	 on	 protein	 quality	 control	 and	events	 such	 as	 accumulation	 of	 misfolded	 or	 aggregate-prone	 proteins	 could	occur	[116]	[117].	In	addition,	also	this	study	is	mostly	 limited	by	 in	vitro	analysis.	Whether	these	results	 can	 be	 applied	 in	 human	 settings	 still	 needs	 further	 clarification.	 	 To	confirm	our	hypothesis,	our	in	vitro	data	should	first	be	corroborated	by	in	vivo	studies.		Nonetheless,	this	study	greatly	enhances	our	knowledge	on	the	protective	effect	of	 IGF-1	 in	 statin-induced	 toxicity,	 and	 increases	 hope	 to	 develop	 efficient	therapeutic	approaches	for	counteracting	muscle	toxicity	associated	with	statin	use.		
Simvastatin	induces	mitochondrial	dysfunction	and	
increases	atrogin-1	expression	in	H9c2	cardiomyocytes	
and	mice	in	vivo		
While	 side-effects	 of	 statins	 in	 skeletal	 muscle	 are	 well-reported	 [2]	 [19]	 [3],	very	 little	 is	known	of	 their	effect	on	cardiac	muscle.	Therefore,	 the	 last	aim	of	
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this	 thesis	 was	 to	 investigate	 on	 the	 effects	 of	 simvastatin	 treatment	 in	cardiomyocytes.	This	work	is	particularly	important	as	statins	are	first-line	treatment	of	choice	to	prevent	 and	 cure	 cardiovascular	 disease.	 Thus,	 cardiac	 side-effects	 may	 be	masked	by	falsely	attributing	them	to	the	underlying	disease.		Previous	 works	 showed	 that	 lovastatin	 reduces	 survival	 of	 cardiomyopathic	hamsters	treated	with	lovastatin	[118]	and	cardiomyocyte	viability	[119]. In	 the	present	 study,	we	showed	 that	 simvastatin	elicited	a	 concentration-	and	time-dependent	decrease	in	cell	viability	in	H9c2	rat	cardiomyoblasts.		Accordingly,	 simvastatin	 exerted	 a	 reduction	 in	 ATP	 content	 linked	 to	mitochondrial	impairment.	Consequently,	the	depression	of	the	intracellular	ATP	levels	activated	AMPK,	which	in	turn	led	to	a	nuclear	translocation	of	Foxo3a	,	a	subsequent	up-regulation	of	atrogin-1	mRNA	levels	and	induction	of	atrophy	and	apoptosis.	Our in	vitro observations were confirmed in C57BL/6	mice	treated	with	5	 mg/kg	 body	 weight/day	 simvastatin	 for	 21	 days.	 These	 findings	 are	 in	accordance	 with	 previous	 work	 that	 reported	 that,	 in	 vitro,	 lipophilic	 statins	induce	cytotoxicity	of	cardiac	myocytes	triggering	apoptosis	[120-123].	In	 conclusion,	we	 showed	 that	 statin-induced	 cardiotoxicity	 is	 triggered	 by	 an	mitochondrial	 impairment	 that	 lead	 to	 atrophy	 and	 apoptosis	 via	AMPK/FoxO/Atrogin-1	 signalling	 pathway.	 Moreover,	 apoptosis	 was	 also	triggered	by	a	separated	mitochondrial	signalling.	Indeed,	the	ratio	Bcl-2/Bax	in	simvastatin-treated	mice	was	low.	Although	 these	 observations	 cannot	 yet	 be	 extrapolated	 in	 humans,	 our	 data	show	 for	 the	 first	 time	 that	 simvastatin	 induces	 signs	 of	 atrophy	 in	cardiomyocytes.	 It	 remains	 to	 be	 determined	 whether	 chronic	 therapy	 with	statin	 in	 human	 could,	 in	 some	 circumstances,	 induce	 cardiac	 atrophy	 with	consequent	 complications,	 analogous	 to	 the	 reduced	 survival	 observed	 in	cardiomyopathic	hamsters	treated	with	lovastatin	[118].	Neverthelss,	in	another	point	 of	 view,	 if	 our	 findings	 would	 be	 confirmed	 in	 a	 clinical	 setting,	 statins	could	 be	 used	 for	 the	 treatment	 of	 cardiomyocyte	 hypertrophy,	 which	 is		strongly	 associated	 with	 obesity	 [124,	 125].	 It	 is	 worth	 to	 notice	 that	 the	cardiotoxic	 effect	 could	be	 just	 a	 consequence	of	high	dose	of	 simvastatin.	The	concentration	 we	 used	 in	 vitro	 exceeds	 the	 peak	 reached	 in	 the	 plasma	 of	
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patients	which	 is	about	1	µM	[61].	However,	 localized	concentration	 in	a	single	organ	could	be	higher,	especially	if	statins	are	combined	with	cytochrome	P450	inhibitors	or	with	impaired	activity	of		OATP1B1	[57]	[29].	With	 the	 rising	 incidence	 and	 prevalence	 of	 cardiovascular	 diseases,	 the	consequent	 increasing	 use	 of	 statins	 and,	 the	 inability	 of	 cardiomyocytes	 to	regenerate,	there	is	an	urgent	need	to	evaluate	the	statin	safety	in	heart	muscle.	Therefore,	 further	 works	 are	 required	 to	 expand	 on	 this	 topic	 and	 fully	determine	any	harmful	effects	of	statins	on	heart	in	human.			
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Important	points	
In	this	study,	we	showed	that	C2C12	myotubes	are	more	susceptible	to	lipophilic	statins	than	to	hydrophilic	statins.	The	different	susceptibility	is	correlated	with	the	ability	to	inhibit	AKT/mTOR	signaling	pathway.	In	addition,	we	showed	the	preventive	effects	of	IGF-1	on	statin-associated	toxicity	in	skeletal	muscle.		Moreover,	 we	 uncovered	 the	 toxicity	 of	 simvastatin	 on	 cardiac	 muscle.	 This	toxicity	is	associated	with	the	mitochondrial	 impairement,	 induction	of	atrophy	and	apoptosis.		Overall,	this	thesis	unravels	the	causative	mechanisms	of	statin-induced	toxicity	and	 has	 significant	 implications	 for	 development	 of	 new	 therapies	 to	 directly	prevent	statin-induced	muscle	damage.						
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